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3Abstract
The assessment of whole body amino acid and protein metabolism from
tracer kinetic data to describe healthy conditions and disease states has
been widely performed for many years by means of primed-constant infu-
sion protocols that only provide limited non-compartmental information.
Given the critical and clinical importance of such topic, there is a need for
a more accurate, detailed modeling of Phenylalanine (Phe) and Tyrosine
(Tyr) metabolism to describe whole body protein synthesis and breakdown
in humans, especially as far as pulse protocols are concerned. In this thesis,
two compartmental models of Phe and Tyr metabolism in healthy subjects
were developed, by using two stable isotope tracer pulses administered in-
travenously. Kinetic analysis was performed on the three tracer responses
in plasma expressed by tracer-tracee ratios and obtained by LC-MS/MS by
isotope dilution. The simplest model (Model 1) provides an important and
physiologically relevant overview of Phe and Tyr metabolism (in terms of
intervals of validity) than the non-compartmental approaches presented in
the past. One of the limit case scenarios (Model 1.a) described by this model
shows results that are compatible with those found using less structurally
complex approaches. Nevertheless, the other limit case scenario (Model 1.b)
is likely to be better representative of changes in protein synthesis and break-
down in tissues like muscle, thanks to the development of a more complex
and elaborate compartmental model (Model 2). This last model provides
accurate estimates for all the unknown parameters, gathers innovative and
detailed structural informations for the metabolism of Phe-Tyr kinetics and
was validated by using results from a continuous infusion experiment on pigs.
The models presented in this thesis could serve not only as a useful refer-
ence for a more complete and physiologically based overview of the Phe and
Tyr metabolic pathways but they could also guide future developments in
the modeling of amino acids characterized by resembling structural proper-
ties. By describing the postabsorptive whole body protein kinetics in healthy
humans the models provide a direction to accurately and comprehensively
assess alterations in whole body protein synthesis and breakdown rates in
disease states.
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Introduction
The assessment of whole body amino acid and protein metabolism from
tracer kinetic data to describe healthy conditions and disease states has been
widely performed for many years by means of primed-constant infusion proto-
cols that only provide non-compartmental information [15, 16, 8, 14, 36, 35].
Only in rare cases this was done by means of compartmental mathematical
analysis, usually after a pulse injection [11, 31, 5]. One of the reasons for the
limited development of compartmental models that provide a comprehen-
sive, accurate description of amino acid and protein kinetics is the inherited
complexity of the system [4], as whole body metabolism needs to be trans-
lated to compartments in the body. Tracer non-compartmental approaches
currently in use are a good source of information to describe some features of
the observed system, but give a limited physiological insight of the structural
compartmental characteristics. Unlike the non-compartmental approaches,
compartmental modeling involves the postulation of a specific compartmen-
tal structure [7]. Compartments must be based on available physiological
information, numerical identification from the experimental data and sub-
sequent validation. Given the critical and clinical importance of describing
whole body protein metabolism in health and disease, there is a need for
a more accurate, elaborate modeling of Phenylalanine (Phe) and Tyrosine
(Tyr) metabolism to describe whole body protein synthesis and breakdown
in humans [26].
In this thesis the development of two models of Phe and Tyr kinetics is pre-
sented, in order to better describe postabsorptive whole body protein kinet-
ics in healthy humans. To do this, a multiple-tracer database was generated
and two compartmental models of different complexity were proposed. Both
models allow the measurement of important Phe and Tyr kinetic events,
including the estimates of the Phe and Tyr involved in the Phe to Tyr con-
version, and the conversion flux from Phe to Tyr. The simplest model only
provides intervals of validity of the estimates of all the other fluxes and pools,
but uses minimal assumptions on the model structure. The more complex
model is uniquely identifiable, thanks to some structural assumptions made
in the design phase which were validated using results from a continuous
infusion experiment on pigs. Both models also allowed the identification of
an issue related to the mixing properties of the accessible Tyr pool in the
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first minutes after the pulse injection. It is important to point out that non-
compartmental approaches cannot address this.
The models presented in this thesis could serve not only as a useful refer-
ence for a more complete and physiologically based overview of the Phe and
Tyr metabolic pathways but they could also guide future developments in
the modeling of amino acids characterized by resembling structural proper-
ties. By describing the postabsorptive whole body protein kinetics in healthy
humans the models provide a direction to accurately and comprehensively
assess alterations in whole body protein synthesis and breakdown rates in
disease states.
This thesis is the result of a collaboration between the Department of Infor-
mation Engineering (DEI), University of Padova and the Center for Transla-
tional Research in Aging and Longevity (CTRAL), Texas A&M University.
The work was conducted under the combined supervision of Prof. Gianna
Maria Toffolo (DEI) and Prof. Nicolaas EP Deutz (CTRAL).
Chapter 1
Background
1.1 Amino Acids and Proteins: General Physiolog-
ical Notions
At least 30 different amino acids are found in nature. It was thought for
some time that only 20 amino acids were present in mammalian, but is now
known that there are 21 (being the 21st selenocysteine, Table 1.1). The
study of amino acid metabolism is considerably more complex than that of
either glucose or lipid, given that the metabolism of each amino acid is dif-
ferent from the others. Nevertheless, a general understanding of the general
principles of amino acid metabolism is of great utility. Protein represents
the second largest store of chemical energy in the body, but it is not typi-
cally used for generating ATP, except from some disease states and extreme
conditions (e.g. very sustained exercise, prolonged starvation). The largest
deposit of protein in the body is in skeletal muscle (about 40% of total body
weight). The synthesis of protein requires amino acids, whereas degradation
of proteins produces amino acids and the two processes occur simultaneously.
Hence, there is a perpetual turnover of protein, which accounts for 20% of
the resting energy expenditure. Free amino acids comprise only 1% of the
total amino acid N, which means that 99% of the amino acids in the body
is bound in proteins.
1.1.1 Intra and Extracellular Concentrations of Amino Acids
in Humans
A general overview of the intracellular concentrations of amino acids in
plasma, liver and muscle is shown in Table 1.2, keeping in mind that the
values reported by authors in the literature vary slightly.
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Table 1.1: The 21 amino acids present in mammalian proteins
Standard Abbreviation
Amino acids in proteins 3-Letter 1-Letter Molecular Mass
Essential (indispensable)
Histidine His H 155
Isoleucine Ile I 131
Leucine Leu L 131
Lysine Lys K 146
Methionine Met M 149
Phenylalanine Phe F 165
Threonine Thr T 119
Tryptophan Trp W 204
Valine Val V 117
Non-essential (dispensable)
Alanine Ala A 89
Arginine Arg R 174
Aspartate Asp D 133
Cysteine Cys C 121
Asparagine Asn N 132
Glutamate Glu E 147
Glutamine Gln Q 146
Glycine Gly G 75
Proline Pro P 115
Serine Ser S 105
Tyrosine Tyr Y 181
Selenocysteine 168
Data from Matthews (2006). The single letter abbreviations are often used
to indicate amino acid sequences in proteins. Molecular mass is rounded to
the nearest whole number and represents the number of grams per mole of
amino acid. Cysteine and Tyrosine are described as conditionally essential
amino acids.
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Table 1.2: Concentrations of free amino acids in Plasma, Liver and Muscle
Concentrations (mmol/L)
Amino acid Plasma Liver Muscle
Alanine 0.36 3.2 3.2
Arginine 0.06 0.03 0.57
Aspartic acid 0.01 18.7 1.0
Asparagine 0.05 0.32 0.40
Cysteine 0.09 - 0.16
Glutamic acid 0.02 4.1 3.8
Glutamine 0.60 5.1 20.0
Glycine 0.20 3.7 1.5
Histidine 0.07 0.77 0.40
Isoleucine 0.05 0.10 0.10
Leucine 0.11 0.30 0.24
Lysine 0.16 0.25 1.2
Methionine 0.02 0.05 0.1
Phenylalanine 0.06 0.10 0.09
Proline 0.22 - 1.6
Serine 0.10 1.0 0.71
Taurine 0.07 8.5 25.0
Threonine 0.11 0.55 0.67
Tryptophan 0.04 0.03 0.1
Tyrosine 0.05 0.15 0.14
Valine 0.21 0.32 0.30
Data from Blomstrand et al. (1995), Matthews (2006), Barle et al. (1996).
Values reported by the authors vary slightly. Taurine is a sulphur amino acid,
not present in proteins. For the calculation from the amount in fresh (wet)
tissue, it is assumed that the intracellular water makes 40% of the weight.
The concentrations of selenocysteine have not been measured. The total
concentration of all the essential amino acids (without cysteine) is the same
in muscle and liver. Similarly the total concentration of all the non-essential
amino acids (excluding taurine) is similar.
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1.1.2 Sources of amino acids
There are four sources of amino acids that enter the free amino acid pool in
the body: proteins in food, proteins secreted into the stomach and intestine
by the digestive glands, endogenous proteins and microorganisms that die
and release their protein in the colon.
• Food : In developed countries, the average daily intake of proteins is
approximately 90 g. During digestion, proteins are hydrolyzed to re-
lease amino acids that are absorbed into the enterocytes of the small
intestine and then enter the blood, from where they are taken up by
tissues for peptide and protein synthesis or to enter the pathways of
metabolism. Free amino acids are present in food, but the amounts
are typically negligible.
• Small intestine and pancreas: Daily, about 70 g of protein enter the
intestine lumen from secretory cells in the form of digestive enzymes
and mucus and from desquamated epithelial cells.
• Endogenous protein: The protein turnover process involves hydrolysis
of cellular protein, with release of free amino acids into the intracellular
compartment.
• Bacterial and other microorganisms in the intestine: These are present
mainly in the colon. Death of the microorganisms is followed by their
digestion and the release of amino acids into the lumen. The amino
acids are then available for use by other microorganisms, by the colono-
cytes or the liver, after their uptake from the lumen. The use by the
liver is quantitatively significant in some conditions.
1.1.3 Protein Turnover
Protein turnover in an adult is approximately 4 to 5 g per kg body weight,
which equals about 250 to 350 g of protein hydrolyzed and resynthesized
in the tissues of an adult human on a daily basis. This number represents
significantly more protein than what is ingested in food. Depending on the
nature of the protein, the condition of the subject and the tissue considered,
the rates of protein turnover vary enormously. Proteins (mainly enzymes)
in the liver are replaced every few hours/days whereas structural proteins
(e.g. contractile proteins, collagen) are stable for several months. Under
some particular conditions, contractile proteins can be degraded relatively
rapidly.
There are two main reasons for protein turnover. First, abnormal proteins
can arise in cells because of spontaneous denaturation, errors in protein
synthesis/translational processing and failure of the correct folding of the
protein or damage by free radicals. They are then degraded and replaced
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by newly synthetized proteins. Secondly, turnover helps keeping stable the
concentration of free amino acids both within cells and in the blood, which
is fundamental to satisfy the requirements for synthesis of essential proteins
and peptides (e.g. hormones).
Turnover is a large-scale substrate cycle, whose role (among others) is to
regulate the concentration of specific proteins. Hence, the turnover rate of
enzymes that control metabolism should be highest, since their activity and
therefore concentration is of key importance in the regulation of metabolism.
The greatest sensitivity of control, which relates to the greatest precision pro-
vided by a cycle, is achieved when there is a high rate of cycling compared to
the net rate of synthesis or degradation. Also, the rate of protein turnover
is directly proportional to the rate of energy expenditure (i.e. energy expen-
diture depends partially on rates of protein turnover).
The three pathways responsible for intracellular protein degradation are: the
lysosomal-autophagic, ubiquitin-proteasome and calpain-calpastatin system.
Although hydrolysis of the peptide bonds does not involve ATP, the various
processes of protein degradation require considerable expenditure of energy,
possibly more than is required for protein synthesis. Nevertheless, the con-
trol of the protein degradation process is very little known, whereas much is
known about the control of protein synthesis.
1.1.4 Defects in protein degradation and diseases
When a protein is lost, it must be replaced in order to maintain health:
excessive loss contributes to death (typically directly caused by infection or
heart failure), as it happens during prolonged starvation or cachexia. In
the elderly, trauma, major surgery or poor nutrition can result in loss of
so much skeletal muscle that normal daily activities (e.g. walking, climb-
ing stairs, dressing, etc.) are impaired. Due to the important role of the
proteasomal-ubiquitin system in the degradation of cellular proteins or pro-
teins of pathogens, any defect in this system could result in disease. In-
deed, the accumulation of insoluble proteins that form aggregates in neurons
(caused by impaired proteolytic digestion of proteins) is suspected to be one
of the possible triggering reasons for some neurodegenerative diseases (e.g.
Alzheimer’s, Parkinson’s, spongiform encephalopathies and motor neuron
diseases). Furthermore, failure to control the rate of degradation of cyclins
could lead to their over-expression, resulting in an increased risk of tumor
development.
1.1.5 Essential and non-essential amino acids
For protein synthesis to take place, all the amino acids must be available
within the cell. To this extent, all amino acids are essential. Nevertheless,
animal studies have demonstrated that some amino acids are essential for
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maintaining nitrogen balance and growth, whereas others are not. This led
to the division between essential and non-essential amino acids. The terms
indispensable and dispensable are also used, but the difference in their mean-
ing is important. From a biochemical standpoint, non-essential amino acids
are those for which a synthetic pathway is present in the body, which is of
sufficient capacity to satisfy the normal requirement. On the contrary, es-
sential amino acids are those for which a synthetic pathway is not present.
In nutritional terms, dispensable amino acids are defined as those that can
be excluded from the diet without affecting nitrogen balance, whereas indis-
pensable amino acids, when excluded from the diet cause negative nitrogen
balance. A negative nitrogen balance (more nitrogen is lost than ingested)
is typical in conditions such as malnutrition, starvation or in some diseases.
A method for determining whether an amino acid is indispensable, it is omit-
ted from the diet while all the others are included. If the omission results
in negative nitrogen balance, the amino acid is deemed indispensable. If,
because of the absence of this single amino acid, the body has been unable
to synthetize proteins, the nitrogen that would have been used in this syn-
thesis is excreted. According to this approach, the following amino acids are
considered to be indispensable for humans: isoleucine, leucine, lysine, me-
thionine, phenylalanine, threonine, tryptophan and valine. Histidine used to
occupy an in between situation, but more recent studies (powered by novel
approaches) have demonstrated that it can be included in the list of essential
amino acids. The non-essential amino acids are alanine, arginine, aspartate,
asparagine, cysteine, glutamate, glutamine, glycine, proline, serine and ty-
rosine. A summary of the reactions involved in their synthesis is given in
Figure 1.1.
Since the distinction between essential and non-essential amino acids is
not always clear-cut, some amino acids become essential only under certain
conditions. The rates of synthesis of some amino acids (glutamine, cysteine
and possibly glycine and arginine) that are normally considered indispens-
able is not sufficient under conditions when their demand is increased (e.g.
during sepsis, after severe trauma or major surgery). Therefore, the essen-
tial nature of these amino acids is conditional. Tyrosine and cysteine can
be synthetized from phenylalanine and methionine, respectively. Given that
both phenylalanine and methionine are indispensable amino acids, if they are
not present in the diet at or below minimal requirement, then there is not
sufficient to synthetize tyrosine or cysteine. For this reason, in such scenario
these amino acids become indispensable, i.e. conditionally essential.
1.1.6 Fate of amino acids
The three major fates of amino acids are three:
• Synthesis of new proteins for growth or repair. The rate of protein
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Figure 1.1: A summary of pathways involved in the synthesis of non-essential
amino acids
synthesis is a major factor determining the overall rate of amino acid
metabolism: the higher its value, the lower the amino acid concentra-
tion, which eventually reduces the rate if catabolism.
• Synthesis of a range of nitrogen-containing small compounds.
• Catabolism. This results, eventually, in formation of ammonia and
small carbon-containing compounds. The carbon skeletons are used for
the synthesis of glucose and triacylglycerol or for a complete oxidation
to carbon dioxide with the generation of ATP. The ammonia is later
converted in urea.
1.1.7 Transport of amino acids into the cell
The metabolism of amino acids takes place within the cell but, before this
can occur, these need to be transported across the plasma membrane. This
requires transport proteins, which have three important characteristics:
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• Since the intracellular concentration of most amino acids is consider-
ably higher than that in plasma, the transport of these amino acids
requires energy. This is achieved via the Na+ gradient across the
plasma membrane, maintained with the usage of ATP.
• There are ten transporters so that some transport more than one amino
acid.
• The properties of some transporters are different in different tissues.
1.1.8 Changes in amino acid metabolism in different condi-
tions
The fed state
The protein in the food is digested and the resultant amino acids are absorbed
from the intestine: these will be used for synthesis of protein and some
nitrogen-containing compounds. Amino acids not required for these two
processes are converted to oxoacids, of which about the half are oxidized for
ATP generation and the other half is converted to glucose (or glycogen); the
ATP generated in the oxidation is used in the conversion to glucose.
Starvation
If starvation lasts for more than 24h, the rate of degradation of body protein
exceeds the rate of protein synthesis. The resultant amino acids are converted
to oxoacids, most of which are converted to glucose which is released and
used predominantly by the brain. In this condition, the ATP required for
gluconeogenesis is obtained from the oxidation of fatty acids.
Trauma, surgery and cancer
In these conditions, in general, the rate of degradation of body protein is
accelerated and the resultant oxoacids are converted to glucose or are ox-
idized. If anorexia is present and the patient is not receiving parenteral
nutrition, oxoacids will be converted mainly to glucose. The synthesis of
some nitrogen-containing compounds is increased for these compounds and
the peptides that are required in this condition (e.g. glutamine, arginine,
cysteine, cytokines, acute phase proteins).
This brief overview is over-simplified but serves to illustrate the central role
played by the changes in amino acid metabolism in the essential physio-
logical processes in these conditions. Some amino acids are metabolized in
tissues other that the liver and description of this metabolism provides a
more realistic picture of whole-body protein and amino acid metabolism in
the body.
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1.1.9 Amino acid metabolism in different tissues
Amino acid metabolism is important in all tissues/organs but some of them
play a key metabolic role
Liver
The liver is the only organ capable of catabolizing all amino acids, with
the important exception of the branched chain amino acids. This makes
physiological sense, since it is the only organ in which ammonia can be
converted into urea and, furthermore, most amino acids that are absorbed
by the gut enter the hepatic portal vein for immediate passage through the
liver. In fact, the liver normally removes and catabolizes more than 70% of
the amino acids that enter this vein. Nevertheless, on a low protein diet, a
lower percentage (especially the essential amino acids) is removed, so that
they are available for other tissues. In general, the liver plays a central role
in the regulation of catabolism of amino acids.
In order to ensure the protection from degradation of the essential amino
acids, with a minimal protein diet, the maximal activities of the enzymes
responsible for the degradation of these amino acids are low. As the intake
of dietary protein increases, the activities of these enzymes increase, due to
acute changes in activity and chronic increases in the amount of enzyme.
Acute regulation of essential amino acid oxidation is achieved via changes
in amino acid concentrations in tissues. The rate of urea production is also
directly proportional to protein intake. This is consistent with the view that
the intracellular concentrations of amino acids play a role in the control of
the rate of catabolism of amino acids (with consequent formation of ammonia
and urea).
The overall rate of amino acid metabolism depends on:
• The concentration of amino acids in the liver
• The activities of the key enzymes that catalyze degradation of the
essential amino acids
• The rate of protein synthesis, in liver and other tissues, which depends
on the concentrations of some hormones and the concentrations of ’sig-
nal’ amino acids
Skeletal muscle
The major role of skeletal muscle is movement. Nevertheless, since muscle
comprises 40% of the body, it is large enough to play a part in control of
the blood concentrations of the major fuels: glucose, fatty acids, triacylglyc-
erol and some amino acids. Skeletal muscle contains the largest quantity of
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protein in the body, which is used as a source of amino acids under various
conditions (e.g. starvation, trauma, cancer).
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1.2 Phenylalanine and Tyrosine in the postabsorp-
tive state: measurement importance and previ-
ous proposed models
The principal reason to measure rates of Phenylalanine (Phe) and Tyro-
sine (Tyr) kinetics in humans is to understand the derangements of the
metabolism of these amino acids that occur in patients with the in-born
error phenylketonuria (PKU) and in diseases that affect their metabolism,
such as in liver or renal disease. PKU is the deficiency of the enzyme Phe
hydroxylase (PAH), which is responsible for the conversion of Phe to other
essential compounds in the body (Figure 1.2), in particular Tyr. This is a
conditionally essential amino acid for PKU patients, because without PAH
it cannot be produced in the body through the breakdown of Phe. Tyr
is necessary for the production of neurotransmitters like epinephrine, nore-
pinephrine and dopamine. Phe, being an essential amino acid, is a necessary
part of the human diet and it is naturally present in all kinds of dietary pro-
tein (it is also used to make aspartame, a sweetener). In healthy subjects,
the PAH enzyme breaks down any excess of Phe beyond what is needed by
the body. However, an insufficiency of the PAH enzyme or its cofactor cause
the building up of Phe in the blood and in the brain to toxic levels, affecting
brain development and function.
Figure 1.2: The reaction converting Phe to Tyr via PAH
Other than that, Phe and Tyr also have specific characteristics as amino
acids that make them useful as markers of protein metabolism. As previously
mentioned, they are both indispensable amino acids, which are essential to
the diet. In the postabsorptive state, there is no entry of amino acids from
dietary sources and the flux of Phe in the body is derived from entry of Phe
released from protein breakdown. Such input is matched by Phe removal via
protein synthesis and via metabolic disposal by conversion to Tyr. There-
fore, in the postabsorptive state the measurement of the rate of appearance
of Phe in plasma is an indicator of the whole body rate of proteolysis, while
the measurement of the conversion rate (hydroxylation flux) of Phe to Tyr
is an index of the net whole body protein breakdown. Additional reasons for
determining Phe and Tyr kinetics are the determination of dietary require-
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ments of these amino acids and the production of Tyr from dietary Phe.
Prior to 1940, there was only circumstantial evidence that Tyr was produced
from Phe, even though authors like Shambaugh, Lewis and Tourtellotte [33]
suggested that Phe was not converted to Tyr. In 1940, a study performed by
Moss and Schoenheimer [28] on rats provided the key evidence on the con-
version and ended the speculation about the metabolism of Phe. Rittenberg,
whose model used 15N-labeled amino acids to determine rates of whole body
protein synthesis in humans, did the very first kinetic study in the 1950s
[32] but many argued on the too many assumptions and limitations of this
approach [20].
What quickly became clear from studies in the 1960s was that measurement
of whole body protein synthesis using tracers is actually very difficult. In
contrast, whole body protein breakdown is easy to measure using an indis-
pensable amino acid tracer. This is due to the concept that the dilution of
the indispensable amino acid tracer in blood occurs due to release of un-
labeled indispensable amino acid from protein breakdown and entry from
the diet [22]. Knowing the rate of indispensable amino acid intake in fed
studies or neglecting this route in postabsorptive subjects, the rate of pro-
tein breakdown is readily calculated from the dilution of an intravenously
infused indispensable amino acid tracer. The first time an indispensable
amino acid was used to measure whole body protein breakdown is dated
1967, in a study performed by James et al. [21] using 14C-Lysine. However,
it was not until 1988 that Darmaun et al. [17] used a 2H5-Phe tracer to
measure Phe kinetics and whole body protein breakdown. Waterlow et al.
[21] tried to use a 14C-Tyr tracer in 1976, but the use of Tyr tracers is an in-
herently problematic affaire when measuring whole body protein breakdown,
due to the unknown amount of Phe converted to Tyr that also provides an
input.
1.2.1 Curtius et al. (1972, 1978) [15, 16]
The early principal use of a deuterated Phe tracer was to assess the conver-
sion of Phe to Tyr, rather than measuring whole body breakdown. Provided
that in normal conditions considerable amounts of Phe are converted to
Tyr, Phe to Tyr conversion is very limited in PKU patients. Curtius et al.
[15] used a 2H-Phe tracer administered in 1 patient as a proof of concept
of this method in 1972 and in 1978 followed up this report by measuring
Phe to Tyr conversion in PKU and hyperphenylalanemic patients [16]. The
approach used by Curtius and al. [15] is shown in the model of Figure 1.3.
The key measurement gleaned here is the enrichment of plasma 2H-
Tyr derived from the conversion of the [phenyl-2H5]-Phe tracer normalized
against the plasma 2H-Phe enrichment. This Tyr/Phe enrichment ratio de-
fines the fraction of free Tyr that is produced from Phe, which in normal
postabsorptive humans should be 15% (given that in this condition 15% of
1.2 Phenylalanine and Tyrosine in the postabsorptive state: measurement
importance and previous proposed models 13
Figure 1.3: The model developed by Curtius et al. [15, 16]
Circles denote the free phenylalanine (Phe) and tyrosine (Tyr) pools. Arrows
indicate rates of appearance and disappearance from the free pools due to
whole body protein synthesis and breakdown. The wide arrow indicates
administration of a Phe tracer (usually by continuous infusion) into the free
Phe pool. Tracer abundance (enrichment) is measured in free Phe and in
Tyr (indicated by the ball and stick figure to denote sampling from the free
pools). The ratio of the Tyr tracer enrichment divided by the Phe tracer
enrichment defines the fraction of free Tyr derived from Phe.
indispensable amino acids are oxidized) [22]. Since a PKU patient is expect
to have undetectable amounts of 2H-Tyr in plasma following the administra-
tion of a 2H-Phe tracer, values between 0 and 15% have been used to classify
the degree of impairment in patients with derangements of Phe metabolism
[25]. Nevertheless, the very limited capacity of conversion in most PKU pa-
tients made the method very difficult to apply with sufficient accuracy in
PKU due to the low enrichment of 2H-Tyr.
1.2.2 Clarke and Bier (1982) [8]
Rather than using Phe tracer conversion to Tyr in order to assess derange-
ments of Phe metabolism, Clarke and Bier [8] used the conversion to define
normal metabolism. As previously addressed, Tyr can become a condition-
ally indispensable amino acid when the availability of Phe (due to limited
intake) is limited for production of Tyr. Therefore, Tyr synthesis in the body
depends upon Phe availability. In a slightly different way to what was done
by Curtius et al. [15, 16], Clarke and Bier’s model needs also the continuous
infusion of a Tyr tracer in order to determine Tyr flux and define the abso-
lute amount of Tyr produced from Phe: they infused a [1-13C]-Tyr tracer in
conjunction with the [phenyl-2H5]-Phe tracer to measure simultaneously the
turnover rates of both Phe and Tyr as well as the rate of Phe conversion to
Tyr. The model for this approach is shown in Figure 1.4.
At the isotopic steady state, the following equations provide the calcula-
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Figure 1.4: The model developed by Clarke and Bier [8]
tions for the variables of the model (Figures 1.4 and 1.5):
E(A) =
in(A)
Fin(A)
(1.1)
E(B) =
in(B)
Fin(B)
(1.2)
E(B←A) = E(A)
Fin2(B)
Fin(B)
(1.3)
Fin2(B) =
E(B←A)
E(B)Fin(B)
(1.4)
Fout(A) = Fin2(B) (1.5)
E(A) and E(B) are the tracer enrichments in plasma of Phe and Tyr,
respectively. E(B←A) is the enrichment for the Phe tracer in Tyr. Fin(A) and
Fin(B) are the input fluxes of Phe and Tyr from protein breakdown (rate of
appearance in plasma). in(A) and in(B) are the the rates of infusion of the
Phe and Tyr tracers. Phe disposal (Fout(A)) is by conversion to Tyr and this
rate equals the rate of Tyr production from Phe (Fin2(B)). Tyr is removed
via Tyr degradation (Fout(B)). Phe has 1 input; Tyr has 2 with the total
input being Fin(B) = Fin1(B) + Fin2(B). This model assumes that only the
entry of unlabeled Phe and Tyr dilutes the tracers, therefore rates of Phe
and Tyr uptake for protein synthesis do not affect tracer enrichments (and
for this reason do not appear in the model).
1.2.3 Cortiella et al. (1992) [14]
The only rate left unsolved in Clarke and Bier [8] model is the rate of tyrosine
oxidation (Fout(B)). The normal approach to measure whole body oxidation
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Figure 1.5: Theoretical time courses of the tracer enrichments for Phe (E(A)),
tyrosine (E(B)), and the Phe tracer in Tyr (E(B←A))
Figure 1.6: Pathway of Tyr degradation.
of a tracer would be to use a 13C or 14C that can be recovered in exhaled
CO2. Figure 1.6 shows the metabolic pathway of Tyr degradation.
The carboxyl carbon of Tyr is almost immediately released as CO2 during
Tyr degradation, the remainder of the molecule either ends up as fumarate
or acetoacetate. Even though both molecules may enter the tricarboxylic
acid cycle and the label recovered as CO2, there are also alternative non-
oxidative fates. For this, a carbon label placed in the phenyl ring of Tyr will
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have a lower recovery in CO2 than a carbon isotope placed in the carboxyl
position. A carboxyl-label is available as the non-radioactive [1-13C]-Tyr,
making it the preferred label for measuring Tyr oxidation.
The first reported use of the [1-13C]-Tyr label for oxidation was the work of
Cortiella et al. [14] in 1992 who also used a [1-13C]-Phe label to measure
Phe oxidation as well. Two series of experiments were performed: one where
6 subjects were continuously infused with [1-13C]-Phe and [2,2-2H2]-Tyr on
day 1, and another where they were continuously infused with [2,2-2H2]-Phe
and [1-13C]Tyr. In both cases, exhaled 13CO2 was determined to define the
rate of 13C-tracer oxidation. The key results of this study are summarized
in Figure 1.7. The Phe flux was determined from the dilution of Phe tracer
in plasma. Tyr flux was determined in a similar way, but its flux is the
sum of Tyr from protein breakdown and Tyr from Phe hydroxylation. The
rate of Phe hydroxylation was determined for each tracer pair from the Phe
tracer appearing as Tyr as described by Clarke and Bier. The oxidation
rates of Phe and Tyr were determined from the recovery of tracer as 13CO2
in exhaled air.
Figure 1.7: The results of Cortiella et al. [14] model
Phe flux is represented by the bold arrow entering the free Phe pool. Tyr flux
is the sum of the 2 bold arrows entering the free Tyr pool (Tyr from protein
breakdown and Tyr from Phe hydroxylation). Tyr oxidation is represented
by the bold arrow exiting the free Tyr pool. All values are reported as
µmol·kg−1·h−1 and are approximate, because results from the 2 groups of
infusions have been combined.
The results (Figure 1.7) of this study are important because they high-
light some general points. As already mentioned, in the postabsorptive state
the appearance rate of indispensable amino acids into plasma will be pro-
portional to the rate of protein breakdown and the abundance of each amino
acid in protein. For instance, leucine is more than twice as abundant as Phe
in protein on a molar basis and the leucine whole body flux should be more
than double the Phe flux. This relation has been shown in general to be
linear for dispensable amino acids [22]. On this basis, we would expect the
rate of Tyr to be ∼60% that of Phe. According Cortiella et al. [14] study,
this percentage is around 76% (46 and 35 µmol·kg−1·h−1 for the Phe and
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Tyr fluxes from protein breakdown, respectively). We would expect based
upon measurements of indispensable amino acids using 13C or 14C tracers in
postabsorptive humans that oxidation should be in the range of 15 to 20% of
the flux, which should be 7-9 µmol·kg−1·h−1 in this case. Instead, the value
reported by Cortiella et al. is ∼5 µmol·kg−1·h−1. As far as the Tyr oxida-
tion rate from the 13C-Tyr tracer is concerned, we would expect this value
to be ∼6 µmol·kg−1·h−1 based upon the Tyr appearance rate from protein
breakdown (35 µmol·kg−1·h−1) and the previously anticipated obligatory ox-
idation of amino acids in the postabsorptive state. To be fair, Phe that must
be oxidized via Tyr (estimated to be ∼8 µmol·kg−1·h−1) should be added to
the amount, for a total expected Tyr oxidation rate of ∼14 µmol·kg−1·h−1.
This expected value for Tyr oxidation in this case agrees with the measured
value for Tyr oxidation.
At this point is important to observe that the rate of Phe hydroxylation
was probably underestimated, allegedly due to the use of 13C as a label for
Phe. Indeed, if one observes the rate reported in this study for Phe oxi-
dation measured by recovery of the [1-13C]-Phe label in exhaled air (∼7.5
µmol·kg−1·h−1), it would look higher than the rate determined for Phe hy-
droxylation (∼5 µmol·kg−1·h−1). This could be due to the fact that the
release rate of 13C-Phe tracee has to be underestimated by trapping of 13C
label as 13C-Tyr in newly synthetized protein. Therefore, adjusting the rate
of Phe hydroxylation upwards would reduce the rate of Tyr entering from
protein breakdown toward the expected amount.
Concluding, a complete picture of Phe-Tyr metabolism can be accomplished
with 2 tracers (a Phe and a Tyr tracer) and measurement of the Phe tracer
in Tyr. Although a [1-13C]-Tyr tracer is ideal for determining Tyr kinetics
because one would get also a direct measurement of Tyr oxidation, it may
not necessarily be used when combined with a Phe tracer. Although [phenyl-
2H5]-Phe is an obvious cheap choice as a tracer, it may produce a significant
isotope effect during the conversion to [2H4]-Tyr, making this tracer subop-
timal for measuring Phe hydroxylation. Therefore, a [1-13C]-Phe becomes
the desired choice, forcing the use of a [2,2-2H2]-Tyr tracer and forfeit of a
Tyr oxidation rate measurement.
Because Phe is an indispensable amino acid, its flux provides a good rep-
resentation of whole body protein breakdown. One of the more consistent
uses of Phe tracers has been measurement of rates of protein breakdown
in the whole body and in tissues that do not hydroxylate Phe, as muscle.
There are a limited number of indispensable amino acids whose metabolism
and availability of tracers coincide for use of determining protein kinetics in
humans: Phe and Tyr tracers are of key importance in this regard .
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1.3 The need for pulse-based protocols and com-
partmental modeling
All the previously presented models for the measurement of Phe-Tyr metabolism
kinetics involved the use of the stable isotope unprimed/primed constant (or
continuous) infusion protocols. These protocols are in general quite tough
to perform, because a lot of time is typically required to achieve the isotopic
plateau at which the kinetic variables can be gleaned. In particular, in the
case of the unprimed constant infusion, this amount of time can become
extremely high. As far as the primed constant infusion is concerned, the es-
timation of the priming dose (that allows to achieve the isotopic steady state
faster) is often odd. Moreover, constant infusion protocols require accurate
infusion pumps, able to infuse consistent amounts of tracer that overall turn
out to be particularly expensive.
In this perspective, pulse-based protocols can lead to great savings in terms
of time and economic resources needed for the study. First of all, the in-
travenous injection of the stable isotope tracer solutions can be performed
directly by nurses, instead of a way more expensive infusion pump. Then,
the amount of tracer is much lower than what is overall required with the
constant infusion protocols, leading to relevant savings in terms of money.
Aside from the more packed sampling schedule needed, the pulse approach
provides the serious overall advantage of a shorter study time. Nevertheless,
the calculations necessary to obtain the kinetic variables of the observed
metabolic pathway with the pulse approach include a higher computational
complexity, due to the need for integrating areas under the curve [36].
Even when these calculations are performed with optimal procedures, the
obtained variables can only provide a limited physiological insight in the
metabolism. For instance, in the postabsorptive state the rate of appear-
ance in plasma of an amino acid is commonly adopted as a measurement of
the whole body protein breakdown. Of course, this is an approximation, be-
cause what appears in plasma is only a limited portion of the total amount of
that amino acid when it is broken down from proteins in tissues [36]. More-
over, most kinetic aspects characterizing amino acid pathways still remain
unknown, especially in the human. The much improved quality of the data
produced in the last few years suggests that it is time to develop novel, more
reliable and higher in complexity compartmental models of measurement for
amino acid kinetics. These models’ aim is to eventually improve the quality
of the gleaned kinetic variables, together with a deeper physiological insight
in the metabolism of amino acids. In fact, only in rare cases the compart-
mental analysis was applied to amino acid research [11, 31, 5]. One of the
reasons for that might be the inherited complexity of the system [4], as whole
body metabolism needs to be translated to compartments in the body, to-
gether with the limited quality of the data in the past.
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For these reasons, in this work a multiple-tracer database was generated with
a single pulse-injection protocol and two compartmental models of different
complexity for the assessment of Phe-Tyr metabolism were formulated and
tested on the dataset.

Chapter 2
Methods
2.1 Dataset
The dataset is a courtesy of the Center for Translational Research in Aging
and Longevity (CTRAL), Texas A&M University and was obtained as part
of the OCERA Study.
2.1.1 Study Population: anthropometric data and body com-
position
The study population consisted of 11 healthy subjects (Table 2.1). The
subjects were recruited via flyers in the local community and subsequently
screened. Written informed consent was obtained from all subjects and the
study was approved by the Institutional Review Board, Texas A&M Univer-
sity.
Body weight was measured by a digital beam scale and height by a stadiome-
ter. Whole body fat-free mass (FFM) was obtained by dual-energy X-ray
absorptiometry (Hologic QDR 4500/ Version 12.7.3.1 (Bedford, MA)).
2.1.2 Study protocol
All subjects were studied at the Clinical Research Unit of the Center for
Translational Research in Aging and Longevity, Texas A&M University. The
study day started in the early morning after an overnight fast and lasted
for approximately 3 hr. A solution (8.1 mL vol) that contained the stable
isotopes of L-[ring-13C6]-Phe (37 mM) and L-[ring-
2H4]-Tyr (2.5 mM) was
prepared (Cambridge Isotope Laboratories (Woburn, MA, USA)). The so-
lution was made iso-osmolar (300 mOsm) by adding NaCl. Body weight,
height and vital signs were measured, and a peripheral line was placed in an
antecubital vein of the arm for infusion of the stable isotopes (Table 2.1). A
second catheter for arterialized venous blood sampling was placed in a su-
perficial dorsal vein of the hand or lower arm of the contralateral arm. The
21
22 Methods
Table 2.1: Subject Characteristics
Subject Gender Age BW FFM FFM DosePhe+6 DoseTyr+4
(ID) (kg) (kg) (%BW) (µmol) (µmol)
A M 55 87.2 65.1 75 301.224 20.049
B F 56 91.3 50.8 56 298.267 19.852
C M 65 95.3 68.3 72 299.006 19.901
D M 69 87.2 67.6 77 294.202 19.582
E M 50 87.2 65.1 75 297.898 19.828
F F 53 68.4 41.6 61 303.072 20.172
I F 60 91.1 45.3 50 302.333 20.123
L M 48 90.5 70.8 78 300.854 20.024
M M 44 86.4 61.4 71 300.485 20.000
N F 69 70.2 39.5 56 299.376 19.926
Q F 54 90.6 51.6 57 300.115 19.975
BW is Body Weight, FFM is Fat-Free Mass, DoseAA+i is the injected dose of
AA+i (at time t=0 minutes. The subscript AA denotes the amino acid (Phe
or Tyr) and subscripts +6 and +4 represent the component of the tracer
(L-[ring-13C6] and L-[ring-2H4], respectively).
hand was placed in a thermostatically controlled hot box (internal temper-
ature: 55◦C), a technique to mimic direct arterial sampling [1]. Before i.v.
administration of the isotopes, a venous blood sample was collected to mea-
sure baseline tracer enrichments. All isotopes are from Cambridge Isotope
Laboratories (Woburn, MA, USA). Arterialized-venous blood was sampled
for 2 hours for analysis of tracer enrichments and concentrations of amino
acids. Samples were collected at the timepoints t=5, 10, 15, 20, 28, 40, 50,
58, 90, 120 minutes.
2.1.3 Biochemical Analysis
Arterialized-venous blood was put in Li-heparinized tubes (Becton Dickinson
Vacutainer system, Franklin Lakes, New Jersey, USA), immediately put on
ice to minimize enzymatic reactions, and centrifuged (4◦C, 3120 x g for 5 min)
to obtain plasma. 250 µl Of plasma was put in 50% sulfosalicylic acid (SSA)
for deproteinization. Samples were instantly frozen and stored at -80◦C until
further analysis. Tracer enrichments [tracer:tracee ratio (TTR)] and plasma
amino acid concentrations were analyzed by LC-MS/MS by isotope dilution
[24]. All samples were analyzed in one batch.
The tracer-tracee ratio as described by Buckley [6] and Cobelli [12, 13] was
used for the (non) compartmental modeling.
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2.2 Non Compartmental Analysis
SAAM II (Version 1.2.1, SAAM Institute, University of Washington) was
used to perform the multiexponential fit of the three measured TTR decays
(L-[ring-2H4]-Tyr, L-[ring-
13C6]-Phe and L-[ring-
13C6]-Tyr). Measurement
errors were assumed to be Gaussian i.i.d. with zero mean and a constant
fractional SD of 0.01. The precision of the estimates was determined from
the inverse of Fisher information matrix.
2.2.1 Optimal Order Selection
The first step of the non-compartmental analysis is the selection of the opti-
mal order of the multiexponential fit of each TTR curve (L-[ring-2H4]-Tyr,
L-[ring-13C6]-Phe and L-[ring-
13C6]-Tyr) to be used in the individual esti-
mates. To do this, the mean subject (data average of each TTR curve)
was chosen as representative of the study population. Single pulse injected
L-[ring-13C6]-Phe (ya(t)) and L-[ring-
2H4]-Tyr (yb(t)) mean subject TTR
curves were fitted by means of the 1-exponential ((2.1) and (2.4), respec-
tively), 2-exponential ((2.2) and (2.5), respectively) and 3-exponential ((2.3)
and (2.6), respectively) data models:
ya(t) = A1e
−a1t (2.1)
ya(t) = A1e
−a1t +A2e−a2t (2.2)
ya(t) = A1e
−a1t +A2e−a2t +A3e−a3t (2.3)
yb(t) = B1e
−b1t (2.4)
yb(t) = B1e
−b1t +B2e−b2t (2.5)
yb(t) = B1e
−b1t +B2e−b2t +B3e−b3t (2.6)
Metabolite L-[ring-13C6]-Tyr (yc(t)) appearance and decay in the mean
subject’s TTR curve was fitted by means of the 2-exponential (2.7) and
3-exponential (2.8) data models:
yc(t) = C1e
−c1t + C2e−c2t (2.7)
yc(t) = C1e
−c1t + C2e−c2t + C3e−c3t (2.8)
The constraints C1 + C2 = 0 and C1 + C2 + C3 = 0 were used in (2.7)
and (2.8), respectively in order to describe the curve properly. Goodness of
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the fit (weighted residuals pattern), precision of the estimates, AIC (Akaike
Information Criterion) were the ingredients used to assess the optimal order
of each TTR curve for the individual non-compartmental analysis.
2.2.2 Individual Analysis
As the optimal order selection results suggests (Section 3.1.1), single pulse in-
jected L-[ring-13C6]-Phe (ya(t)) and L-[ring-
2H4]-Tyr (yb(t)) individual TTR
decay curves were fitted by means of the 2-exponential data model ((2.2)
and (2.5), respectively), while metabolite L-[ring-13C6]-Tyr (yc(t)) appear-
ance and decay in the individual TTR curves were fitted by means of the
3-exponential data model (2.8).
The estimation of the unknown parameters (A1, A2, a1, a2, B1, B2, b1, b2,
C1, C2, C3, c1, c2, c3) was performed both by considering all data points and
by discarding samples at t=5 and 10 minutes in Tyr TTR curves, in order
to verify the impact of such assumption (as it was made necessary by the
compartmental analysis). The unknown parameters were used to compute
areas under the curve (AUCAA+i) as described by the following formulae
[36]:
AUCPhe+6 =
A1
a1
+
A2
a2
(2.9)
AUCTyr+4 =
B1
b1
+
B2
b2
(2.10)
AUCTyr+6 =
C1
c1
+
C2
c2
+
C3
c3
(2.11)
The rates of appearance (Ra,Phe) of every amino acid in plasma and the
conversion rate of Phe to Tyr (Phe → Tyr) were then obtained according
to the following equations [36]:
Ra,Phe =
DosePhe+6
AUCPhe+6
(2.12)
Ra,Tyr =
DoseTyr+4
AUCTyr+4
(2.13)
Phe→ Tyr = Ra,TyrAUCTyr+6
AUCPhe+6
(2.14)
DoseAA+i denotes the amount of the bolus of tracer administered at
time t=0 min, the subscript AA denotes the amino acid (Phe or Tyr) and
subscripts +6 and +4 represent the component of the tracer (L-[ring-13C6]
and L-[ring-2H4], respectively).
2.3 Compartmental Analysis 25
2.3 Compartmental Analysis
The bolus of L-[ring-2H4]-Tyr and L-[ring-
13C6]-Phe isotopes enables the
measurement of the Tyr and Phe kinetics. Furthermore, the portion of the
L-[ring-13C6]-Phe isotope that is converted into L-[ring-
13C6]-Tyr is reflected
by the tracer-tracee ratio (TTR) of L-[ring-13C6]-Tyr detected in plasma.
Using the plasma TTRs of Phe and Tyr, two compartmental models were
developed to analyze the tracer and tracee data.
The first step in model identification is the a priori identifiability analysis of
the model [9], which determines whether the model with its input-output ex-
perimental configuration has a unique or multiple solutions for its parameters
given the ideal condition of noise-free data and error-free model structure.
This a priori identifiabilty analysis was done by using the program DAISY
(Version 1.9, University of Cagliari and University of Padova) [3] for both
models. The numerical identification of the models was performed by using
the modeling software SAAM II (Version 2.2.1, SAAM Institute, University
of Washington) [2]. Measurement errors were assumed to be Gaussian i.i.d.
with zero mean and a constant fractional SD equal to 0.01. The precision
of the parameters estimates was determined from the inverse of the Fisher
information matrix.
Tyr samples at t=5 and 10 minutes were not considered, since they were sys-
tematically underestimated. It is likely that the first two samples of the Tyr
curves might have been affected from a mixing pool issue [21, 27]. Further
details are presented in Chapter 4.
2.3.1 The Four Compartments Model (Model 1)
The previously described non-compartmental analysis suggests that a simple
compartmental model made up by four compartments, two compartments for
each amino acid, could describe data with the same reliability [36].
The Model is shown in Figure 2.1. Both compartments 1 and 2 represent Phe:
Compartment 1 is the pool in which Phe is sampled and represents plasma
and rapidly equilibrating tissues, while Compartment 2 represents Phe in
tissues that are exchanging with Compartment 1 with a slower kinetics. Ir-
reversible losses from both compartments 1 and 2 represent protein synthesis.
Similarly to Phe, compartments 3 and 4 represent Tyr. Irreversible losses
from both compartments 3 and 4 represent protein synthesis and oxidation.
The link between compartments 1 and 3 represents the hydroxylation flux
of Phe into its metabolite Tyr which takes place in fast exchanging tissues
[26]. L-[ring-13C6]-Phe and L-[ring-
2H4]-Tyr were introduced into compart-
ments 1 and 3 respectively and the corresponding tracer-tracee ratio data
was measured in plasma, while a portion of the L-[ring-13C6]-Phe isotope
is converted into L-[ring-13C6]-Tyr and its tracer-tracee ratio data was also
measured in plasma (Compartment 3 in the model).
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The tracer model is described by the following equations:
• Tracer 1 (L-[ring-13C6]):
dq+61
dt
(t) = −(k01 + k21 + k31)q+61 (t) + k12q+62 (t) + u1 (2.15)
dq+62
dt
(t) = k21q
+6
1 (t)− (k02 + k12)q+62 (t) (2.16)
dq+63
dt
(t) = k31q
+6
1 (t)− (k03 + k43)q+63 (t) + k34q+64 (t) (2.17)
dq+64
dt
(t) = k43q
+6
3 (t)− (k04 + k34)q+64 (t) (2.18)
• Tracer 2 (L-[ring-2H4]):
dq+43
dt
(t) = k31q
+4
1 (t)− (k03 + k43)q+43 (t) + k34q+44 (t) + u2 (2.19)
dq+44
dt
(t) = k43q
+4
3 (t)− (k04 + k34)q+44 (t) (2.20)
Where qi is tracer mass of compartment i (i = 1, 2, 3, 4), with the initial
condition qi(0) = 0; qi is the sum of the labeled (artificially elevated in the
tracer) and the unlabeled (predominating in the tracee) species due to the
exogenously introduced material. The superscripts +6 and +4 denote the
components of the tracers L-[ring-13C6] and L-[ring-
2H4], respectively. u1
and u2 are the pulse tracer inputs of Phe and Tyr, respectively. The three
measurement equations are:
TTR1(t) =
q+61 (t)
Q1
(2.21)
TTR2(t) =
q+63 (t)
Q3
(2.22)
TTR3(t) =
q+43 (t)
Q3
(2.23)
Q1 and Q3 are the tracee masses, i.e., the sum of the labeled and unla-
beled species present in the naturally occurring material of compartments 1
and 3, respectively.
The tracee system is assumed to be in steady state during the study period.
Therefore, it is described by the following equations:
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0 = −(k01 + k21 + k31)Q1 + k12Q2 + U1 (2.24)
0 = k21Q1 − (k02 + k12)Q2 + U2 (2.25)
0 = k31Q1 − (k03 + k43)Q3 + k34Q4 + U3 (2.26)
0 = k43Q3 − (k04 + k34)Q4 + U4 (2.27)
Where Qi are the tracee masses and Ui are the endogenous produc-
tions (U1, U2 and U3, U4 of Phe and Tyr, respectively) coming from protein
catabolism. Q1, Q3 and the kij are estimated from the tracer model. The
products kijQj are the fluxes Fij . This way, the disposals F01, F02 represent
Phe going into protein anabolism, while F03 and F04 represent Tyr either
being included in proteins or being oxidized.
Figure 2.1: The four compartments model of Phe-Tyr kinetics (Model 1)
The circles indicate compartments representing kinetically distinct pools of
Phenylalanine and Tyrosine and the arrows between them the intercompart-
mental fluxes. kij (per minute) are the transfer rate constants of flux from
compartment j to compartment i. Large arrows denote Phe (solid arrow)
and Tyr (open arrow) tracer inputs. TTRi measurements are indicated by
dashed lines ending with solid (from Phe tracer input) or open (from Tyr
tracer input) circle, respectively.
Model Identification
The a priori identifiability analysis of Model 1 revealed that the model is
non-uniquely identifiable, meaning that there are multiple solutions for some
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Figure 2.2: Interval identification strategy (Model 1)
Unidentifiable parameters of the model shown in Figure 2.1, Panel A are
quantified in terms of upper and lower bounds of intervals of admissible
values, by use of the two submodels shown in panels B and C.
of the unknown parameters. In particular, k31, Q1 and Q3 are uniquely iden-
tifiable, while all the remaining parameters (k12, k21, etc.) are not uniquely
identifiable. Indeed, this is due to the fact that each amino acid has one
input and two possible exits from the system: the main issue here is that it
is not trivial to find a relationship between the irreversible losses from the
pools of each amino acid. As regards the tracee parameters, U1, U2, U3, U4
and Q2, Q4 cannot be solved from eq. (2.24), (2.25), (2.26), (2.27), since the
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number of unknowns (6) exceeds the number of equations (4). Therefore,
the model described in Figure 1 was used to find upper and lower bounds for
its parameters. To achieve this, estimation from interval identifiable models
[19, 10] was used. The adopted identification strategy is depicted in Figure
2.2 showing how the non-uniquely identifiable tracer/tracee model is split
into two uniquely identifiable submodels: Model 1.a and Model 1.b. The first
submodel (Model 1.a), by setting k02 = k04 = U2 = U4 = 0 provides values
for the uniquely identifiable parameters (Q1, Q3 and k31), upper bounds for
k12, k34, k01, k03, U1, U3, F01, F03 and lower bounds for k21, k43, k02, k04,
Q2, Q4, F21, F12, F43, F34, F02, F04. The second submodel (Model 1.b), by
setting k01 = k03 = U1 = U3 = 0 provides values for the uniquely identifiable
parameters (Q1, Q3 and k31), upper bounds for k21, k43, k02, k04, Q2, Q4,
F21, F12, F43, F34, U2, U4, F02, F04 and the lower bounds for k12, k34, k01,
k03, U1, U3, F01, F03. The hydroxylation flux F31 has a unique solution,
common to both submodels because it is expressed in terms of Q1 and k31
which are uniquely identifiable. Each submodel was numerically identified
in every subject by using nonlinear least-squares to fit the three TTR curves
using the program SAAM II [2].
2.3.2 The Six Compartments Model (Model 2)
The previously described Model provides an useful insight in the metabolism
of Phe-Tyr kinetics in the postabsorptive state, along with accurate measure-
ments for the hydroxylation flux. Nevertheless, the model is non-uniquely
identifiable and only allows possible intervals of estimation for most of the
unknown parameters [19, 10]. In order to overcome this identifiability issue,
the development of a more complex compartmental model was necessary.
Later, it was possible to validate some of the structural assumptions made
in the design phase by using the model to simulate a continuous infusion
experiment previously done on pigs (Section 4.2.6).
The Model is shown in Figure 2.3. Compartments 1, 2 and 5 represent
Phe: Compartment 1 is the pool in which Phe is sampled and represents
extracellular (EC) fluid; Compartment 2 represents intracellular (IC) Phe in
tissues that are exchanging with Compartment 1 with a slow kinetics; Com-
partment 5 represents intracellular (IC) Phe in tissues that are exchanging
with Compartment 1 with a fast kinetics and are responsible for the conver-
sion to Tyr. The irreversible loss from Compartment 2 represents protein
synthesis. Similarly to Phe, compartments 3, 4 and 6 represent Tyr. The
irreversible loss from compartment 4 represents protein synthesis and oxida-
tion. The link between compartments 5 and 6 represents the hydroxylation
flux of Phe into its metabolite Tyr, which takes place at the intracellular level
in fast exchanging tissues [26]. Similarly to Model 1, L-[ring-13C6]-Phe and
L-[ring-2H4]-Tyr were introduced into Compartment 1 and 3 respectively and
the corresponding tracer-tracee ratio data was measured in plasma, while a
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Figure 2.3: The six compartments model of Phe-Tyr kinetics (Model 2)
The notation used is the same of Figure 2.1
portion of the L-[ring-13C6]-Phe isotope is converted into L-[ring-
13C6]-Tyr
and its tracer-tracee ratio data was also measured in plasma (Compartment
3 in the model).
The tracer model is described by the following equations:
• Tracer 1 (L-[ring-13C6]):
dq+61
dt
(t) = −(k21 + k51)q+61 (t) + k12q+62 (t) + k15q+65 (t) + u1 (2.28)
dq+62
dt
(t) = k21q
+6
1 (t)− (k02 + k12)q+62 (t) (2.29)
dq+63
dt
(t) = −(k43 + k63)q+63 (t) + k34q+64 (t) + k36q+66 (t) (2.30)
dq+64
dt
(t) = k43q
+6
3 (t)− (k04 + k34)q+64 (t) (2.31)
dq+65
dt
(t) = k51q
+6
1 (t)− (k15 + k65)q+65 (t) (2.32)
dq+66
dt
(t) = k63q
+6
3 (t) + k65q
+6
5 (t)− k36q+66 (t) (2.33)
• Tracer 2 (L-[ring-2H4]):
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dq+43
dt
(t) = −(k43 + k63)q+43 (t) + k34q+44 (t) + k36q+46 (t) + u2 (2.34)
dq+44
dt
(t) = k43q
+4
3 (t)− (k04 + k34)q+44 (t) (2.35)
dq+46
dt
(t) = k63q
+4
3 (t) + k65q
+4
5 (t)− k36q+46 (t) (2.36)
Where the notation follows the same convention used in Model 1. Sim-
ilarly, the three measurement equations are (2.21), (2.22), (2.23) and the
tracee system is assumed to be in steady state during the study period.
Therefore, it is described by the following equations:
0 = −(k21 + k51)Q1 + k12Q2 + k15Q5 (2.37)
0 = k21Q1 − (k02 + k12)Q2 + U2 (2.38)
0 = −(k43 + k63)Q3 + k34Q4 + k36Q6 (2.39)
0 = k43Q3 − (k04 + k34)Q4 + U4 (2.40)
0 = k51Q1 − (k15 + k65)Q5 (2.41)
0 = k63Q3 + k65Q5 − k36Q6 (2.42)
Where Qi are the tracee masses and Ui are the endogenous productions
(U2 and U4 of Phe and Tyr, respectively) coming from protein catabolism.
kij are estimated from the tracer model, whereas Q1 and Q3 are estimated a
priori from plasma concentrations of Phe and Tyr (see Model Identification
section for further details). The products kijQj are the fluxes Fij . This
way, the disposal F02 represents Phe going into protein anabolism, while F04
represents Tyr either being included in proteins or being oxidized.
Model Identification
The a priori identifiability analysis of Model 2 revealed that the model is
uniquely identifiable, meaning that there is one unique solution for every
unknown parameter. Nevertheless, since samples at t=5 and 10 minutes of
Tyr curves were not considered [21, 27] and the model structure accounts for
2 more compartments than Model 1, estimating the accessible pool sizes Q1
and Q3 directly from the dataset is quite troublesome. Therefore, their di-
mensions were calculated a priori from the fat-free mass (FFM) and plasma
concentrations of Phe and Tyr of every subject, according to the following
equations:
TBW = 0.73 FFM (2.43)
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Table 2.2: A priori estimation of Q1 and Q3
Subject FFM TBW ECvol [Phe]EC [Tyr]EC Q1 Q3
(kg) (L) (L) (µM) (µM) (µmol) (µmol)
A 65.1 47.5 15.8 44.5 46.4 705 735
B 50.8 37.1 12.4 49.9 42.7 617 527
C 68.3 49.9 16.6 54.0 63.6 898 1057
D 67.6 49.4 16.5 41.6 38.2 685 628
E 65.1 47.5 15.8 38.4 42.8 609 677
F 41.6 30.4 10.1 29.9 33.7 303 341
I 45.3 33.0 11.0 41.7 40.7 459 449
L 70.7 51.6 17.2 36.8 38.2 634 657
M 61.4 44.8 14.9 35.6 33.6 532 502
N 39.5 28.8 9.6 42.3 43.6 407 418
Q 51.6 37.7 12.6 36.5 42.1 458 528
Mean 57.0 41.6 13.9 41.0 42.3 573 593
SEM 11.5 8.4 2.8 6.8 8.1 165 195
ECvol =
1
3
TBW (2.44)
Q1 = [Phe]ECECvol (2.45)
Q3 = [Tyr]ECECvol (2.46)
TBW stands for Total Body Water and ECvol for the total extracellular
(EC) volume of the body. [Phe]EC and [Tyr]EC are the extracellular con-
centrations of Phe and Tyr, respectively. It is assumed that [Phe]plasma =
[Phe]EC and [Tyr]plasma = [Tyr]EC . The computed values for every subject
are reported in Table 2.2. The a priori calculated values of Q1 a Q3 were
therefore used in SAAM II as fixed variables.
Because of the limited number of data points available in the first phase
of the experiment (given the already mentioned Tyr mixing issue [21, 27]),
maximum likelihood (ML) estimation of some of the unknown parameters
(k15, k36, k51 and k63) was not possible. For this reason, maximum a priori
(MAP) estimation was used for such kinetic parameters, by means of the
following a priori information:
k15 : µ = 1.016, σ = 0.102 (2.47)
k36 : µ = 1.016, σ = 0.102 (2.48)
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k51 : µ = 0.031, σ = 0.003 (2.49)
k63 : µ = 0.017, σ = 0.002 (2.50)
This a priori information was gleaned based on the assumption that EC
(compartments 1 and 3) and IC pools for hydroxylation (compartments 5
and 6) mix very rapidly [35, 23] and was later validated by using the model
to perform a continuous infusion experiment previously done on pigs (Section
4.2.6).

Chapter 3
Results
3.1 Non Compartmental Analysis
3.1.1 Optimal Order selection
The non-compartmental data models used on the mean subject allow for
some observations. In general, the two-exponential and the three-exponential
models provide a good fit for the L-[ring-13C6]-Phe and L-[ring-
2H4]-Tyr
TTR curves, while the one-exponential model is not able to fit the data
properly, as shown in Figure 3.1. In particular, the mean weighted residu-
als’ patterns (defined for a given time point as the difference between the
datum and the model prediction normalized by the SD of the datum) con-
firmed by visual inspection the goodness of the fit. Nevertheless, for these
two TTR curves the two-exponential data model shows a higher precision
of the estimates compared to the three-exponential one, together with a
lower AIC (tables 3.1 and 3.2). Therefore, it is possible to conclude that a
two-exponential data model is the optimal order for the non-compartmental
fitting of the L-[ring-13C6]-Phe and L-[ring-
2H4]-Tyr TTR curves. As far as
the L-[ring-13C6]-Tyr TTR curve is concerned, the three-exponential model
provides a good fit of the mean subject data, whereas the two-exponential
model is unable to do the same (Figure 3.1). It is therefore possible to
conclude that a three-exponential data model is the optimal order for the
non-compartmental fitting of the L-[ring-13C6]-Tyr TTR curve.
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Figure 3.1: Ability of the non-compartmental data models to fit mean subject
data (optimal order selection)
Average Data (solid dots) vs. model fit (continuous line) in left panels,
weighted residuals in right panels. Weighted residuals are defined as the
difference between data and model prediction normalized to SD of data.
Continuous black line represents one-exponential, continuous blue line rep-
resents 2-exponential and continuous red line represents three-exponential
data models.
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Table 3.1: Mean Subject L-[ring-13C6]-Phe (ya) multiexponential parameters
and AIC
A1 A2 A3 a1 a2 a3 AIC
1-exp 0.125 0.025 8.10(20%) (15%)
2-exp 0.295 0.068 0.121 0.016 10.10(8%) (6%) (7%) (4%)
3-exp 0.288 0.138 0.054 0.243 0.071 0.014 12.10(12%) (24%) (11%) (22%) (18%) (7%)
Ai are adimensional, ai are min−1. The number between brackets indicates
the precision of the estimate, defined as CV% = 100 SD(pi,est)/pi,est, where
CV is the coefficient of variation and SD is the standard deviation.
Table 3.2: Mean Subject L-[ring-2H4]-Tyr (yb) multiexponential parameters
and AIC
B1 B2 B3 b1 b2 b3 AIC
1-exp 0.008 0.021 8.10(15%) (14%)
2-exp 0.013 0.005 0.093 0.014 10.10(5%) (6%) (7%) (5%)
3-exp 0.011 0.006 0.002 0.138 0.034 0.007 12.10(9%) (10%) (67%) (15%) (35%) (57%)
Bi are adimensional, bi are min−1. The number between brackets indicates
the precision of the estimate, defined as CV% = 100 SD(pi,est)/pi,est, where
CV is the coefficient of variation and SD is the standard deviation.
Table 3.3: Mean Subject L-[ring-13C6]-Tyr (yc) multiexponential parameters
and AIC
C2 C3 c1 c2 c3 AIC
2-exp 0.010 0.599 0.015 10.10(10%) (59%) (12%)
3-exp 0.010 0.007 0.629 0.086 0.010 12.10(9%) (7%) (10%) (14%) (7%)
Ci are adimensional, ci are min−1. The number between brackets indicates
the precision of the estimate, defined as CV% = 100 SD(pi,est)/pi,est, where
CV is the coefficient of variation and SD is the standard deviation.
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3.1.2 Individual Analysis
The non-compartmental data model used provides a good fit of experimen-
tal data, shown in figures 3.2 (complete dataset) and 3.3 (Tyr samples at
t=5 and 10 minutes discarded). In particular, the mean weighted residuals’
patterns confirmed by visual inspection the goodness of the fit.
The population averages of every parameter are reported in Table 3.4. The
single subject estimates are reported in tables 3.5 (L-[ring-13C6]-Phe), 3.6
(L-[ring-2H4]-Tyr and L-[ring-
13C6]-Tyr, complete dataset) and 3.7 (L-[ring-
2H4]-Tyr and L-[ring-
13C6]-Tyr, samples at t=5 and 10 minutes discarded).
When all data points were considered, all parameters were estimated with
good precision, as all CV%’s are below 50% (except from Subject N’s C2,
whose CV% is 72%). When samples at t=5 and 10 minutes in the Tyr TTR
curves were not considered, the precision of the estimates of some of the pa-
rameters was not optimal (as the maximum CV% is 104% and 8 parameters
have a CV% above 50%), due to the limited number of data points avail-
able for the estimation. Individual gleaned fluxes are reported in tables 3.8
(complete dataset) and 3.9 (Tyr samples at t=5 and 10 minutes discarded).
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Figure 3.2: Ability of non-compartmental data models to fit data (complete
dataset)
Average Data (solid dots) vs. Average model fit (continuous line) in left
panels, average weighted residuals in right panels.
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Figure 3.3: Ability of non-compartmental data models to fit data (Tyr sam-
ples at t=5 and 10 minutes discarded)
Average Data (solid dots) vs. Average model fit (continuous line) in left
panels, average weighted residuals in right panels.
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Table 3.4: Average non-compartmental multiexponential parameters, AUCs
and non-compartmental fluxes
Variable Unit Complete Dataset Partial Dataset
A1 adimensional 0.299 ± 0.107
A2 adimensional 0.068 ± 0.025
a1 min−1 0.119 ± 0.016
a2 min−1 0.016 ± 0.002
B1 adimensional 0.014 ± 0.006 0.017 ± 0.011
B2 adimensional 0.005 ± 0.002 0.003 ± 0.001
b1 min−1 0.101 ± 0.038 0.090 ± 0.055
b2 min−1 0.014 ± 0.001 0.011 ± 0.002
C2 adimensional 0.013 ± 0.006 0.014 ± 0.007
C3 adimensional 0.007 ± 0.002 0.006 ± 0.001
c1 min−1 0.519 ± 0.066 0.204 ± 0.019
c2 min−1 0.129 ± 0.072 0.081 ± 0.034
c3 min−1 0.010 ± 0.002 0.009 ± 0.001
AUCPhe+6 min 6.582 ± 1.670
AUCTyr+4 min 0.477 ± 0.158 0.501 ± 0.140
AUCTyr+6 min 0.769 ± 0.190 0.759 ± 0.209
Ra,Phe µmol·FFM kg−1·h−1 50.4 ± 4.9
Ra,Tyr µmol·FFM kg−1·h−1 47.8 ± 9.0 44.5 ± 5.7
Phe→ Tyr µmol·FFM kg−1·h−1 5.7 ± 1.5 5.2 ± 1.3
Values are expressed as Mean ± SEM. The Partial Dataset column rep-
resents the condition in which samples at t=5 and 10 minutes were not
considered in Tyr TTR curves for the estimation. C1 is not reported, being
C1 = −(C2 + C3).
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Table 3.5: Individual L-[ring-13C6]-Phe (ya) multiexponential parameters
and AUCs
Subject A1 A2 a1 a2 AUCPhe+6
A Value 0.255 0.050 0.106 0.014 5.884CV% 10 11 10 9 2
B Value 0.185 0.069 0.099 0.013 7.005CV% 6 5 8 5 1
C Value 0.229 0.039 0.116 0.014 4.665CV% 14 13 13 11 4
D Value 0.278 0.046 0.111 0.016 5.443CV% 6 7 6 5 2
E Value 0.301 0.068 0.135 0.018 5.931CV% 14 10 13 6 3
F Value 0.580 0.113 0.148 0.018 10.079CV% 12 7 9 5 3
I Value 0.252 0.075 0.123 0.017 6.469CV% 14 10 14 7 3
L Value 0.263 0.044 0.120 0.017 4.803CV% 13 12 11 8 3
M Value 0.380 0.056 0.141 0.017 5.975CV% 11 8 9 6 3
N Value 0.238 0.110 0.102 0.017 8.970CV% 6 5 8 3 1
Q Value 0.325 0.079 0.114 0.018 7.179CV% 9 8 9 5 2
Mean
Value 0.299 0.068 0.119 0.016 6.582
CV% 10 9 10 6 2
SEM 0.107 0.025 0.016 0.002 1.670
Values are in min−1 (ai), adimensional (Ai), min (AUCPhe+6). Precisions of
estimated parameters are expressed as CV% = 100 SD(pi,est)/pi,est, where
CV is the coefficient of variation and SD is the standard deviation.
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Table 3.6: Individual L-[ring-2H4]-Tyr (yb) and L-[ring-
13C6]-Tyr (yc) mul-
tiexponential parameters and AUCs (complete dataset)
Subj. B1 B2 b1 b2 C2 C3 c1 c2 c3 AUCTyr+4 AUCTyr+6
A Value 0.008 0.003 0.065 0.013 0.010 0.005 0.491 0.045 0.007 0.367 0.894CV% 21 21 28 13 11 32 15 25 40 5 14
B Value 0.011 0.005 0.066 0.013 0.015 0.007 0.533 0.312 0.010 0.508 0.657CV% 16 18 23 12 46 6 16 26 9 4 5
C Value 0.013 0.002 0.111 0.012 0.010 0.004 0.530 0.097 0.009 0.316 0.569CV% 22 21 22 20 21 13 23 23 16 6 7
D Value 0.014 0.003 0.094 0.015 0.017 0.005 0.336 0.076 0.009 0.357 0.758CV% 12 17 15 12 21 27 22 28 36 3 13
E Value 0.012 0.004 0.088 0.014 0.013 0.009 0.566 0.106 0.013 0.405 0.762CV% 11 14 15 10 25 11 22 30 10 3 3
F Value 0.028 0.010 0.204 0.015 0.014 0.012 0.539 0.108 0.010 0.771 1.257CV% 35 9 28 8 31 9 23 35 11 4 5
I Value 0.006 0.004 0.079 0.014 0.007 0.007 0.503 0.181 0.010 0.386 0.727CV% 17 18 33 13 48 6 17 32 8 3 5
L Value 0.015 0.003 0.085 0.012 0.016 0.006 0.545 0.088 0.014 0.403 0.589CV% 12 23 16 20 24 25 23 33 19 4 5
M Value 0.012 0.003 0.098 0.013 0.026 0.007 0.580 0.109 0.010 0.378 0.839CV% 9 10 11 8 19 13 22 18 14 2 5
N Value 0.014 0.006 0.109 0.011 0.001 0.006 0.552 0.169 0.008 0.664 0.753CV% 22 16 28 16 72 3 15 40 5 6 3
Q Value 0.023 0.008 0.113 0.016 0.010 0.007 0.531 0.123 0.012 0.688 0.653CV% 17 13 19 10 28 6 23 24 6 3 3
Mean
Value 0.014 0.005 0.101 0.014 0.013 0.007 0.519 0.129 0.010 0.477 0.769
CV% 18 16 22 13 31 14 20 28 16 4 6
SEM 0.006 0.002 0.038 0.001 0.006 0.002 0.066 0.072 0.002 0.158 0.190
Values are in min−1 (bi, ci), adimensional (Bi, Ci), min (AUCAA+i). Preci-
sions of estimated parameters are expressed as CV% = 100 SD(pi,est)/pi,est,
where CV is the coefficient of variation and SD is the standard deviation.
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Table 3.7: Individual L-[ring-2H4]-Tyr (yb) and L-[ring-
13C6]-Tyr (yc) mul-
tiexponential parameters and AUCs (samples at t=5 and 10 minutes dis-
carded)
Subj. B1 B2 b1 b2 C2 C3 c1 c2 c3 AUCTyr+4 AUCTyr+6
A Value 0.011 0.003 0.065 0.010 0.015 0.006 0.207 0.073 0.009 0.410 0.802CV% 31 31 29 27 32 15 14 29 17 8 6
B Value 0.011 0.003 0.051 0.009 0.020 0.006 0.210 0.144 0.009 0.533 0.675CV% 21 47 30 40 77 6 14 25 8 8 4
C Value 0.042 0.003 0.170 0.013 0.018 0.004 0.211 0.108 0.008 0.449 0.553CV% 58 10 21 9 57 12 14 27 17 21 7
D Value 0.012 0.003 0.092 0.015 0.025 0.006 0.212 0.092 0.010 0.346 0.712CV% 17 9 14 6 41 20 14 28 25 3 9
E Value 0.009 0.003 0.060 0.011 0.011 0.005 0.217 0.045 0.008 0.399 0.787CV% 8 21 15 16 15 17 14 18 16 2 5
F Value 0.009 0.003 0.030 0.008 0.015 0.008 0.149 0.048 0.007 0.758 1.336CV% 15 31 19 27 45 24 29 40 26 8 10
I Value 0.036 0.005 0.198 0.015 0.009 0.007 0.200 0.132 0.010 0.510 0.705CV% 74 4 25 3 72 10 15 29 13 18 7
L Value 0.013 0.002 0.074 0.011 0.013 0.003 0.207 0.045 0.008 0.404 0.594CV% 24 32 25 28 16 33 15 19 32 5 8
M Value 0.009 0.003 0.072 0.012 0.020 0.005 0.220 0.073 0.008 0.367 0.816CV% 13 15 16 12 36 18 30 26 20 2 7
N Value 0.020 0.006 0.140 0.012 0.001 0.006 0.202 0.061 0.008 0.685 0.735CV% 66 11 35 12 104 6 14 76 8 9 4
Q Value 0.012 0.003 0.042 0.009 0.007 0.006 0.213 0.073 0.011 0.653 0.631CV% 12 30 15 25 49 16 14 50 15 5 5
Mean
Value 0.017 0.003 0.090 0.011 0.014 0.006 0.204 0.081 0.009 0.501 0.759
CV% 31 22 22 19 49 16 17 33 18 8 7
SEM 0.011 0.001 0.055 0.002 0.007 0.001 0.019 0.034 0.001 0.140 0.209
Values are in min−1 (bi, ci), adimensional (Bi, Ci), min (AUCAA+i). Preci-
sions of estimated parameters are expressed as CV% = 100 SD(pi,est)/pi,est,
where CV is the coefficient of variation and SD is the standard deviation.
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Table 3.8: Individual non-compartmental fluxes (complete dataset)
Subject Ra,Phe Ra,Tyr Phe→ Tyr
A 47.2 50.3 7.6
B 50.3 46.1 4.3
C 56.3 55.4 6.8
D 48.0 48.7 6.8
E 46.3 45.2 5.8
F 43.3 37.7 4.7
I 62.0 69.1 7.8
L 53.1 42.1 5.2
M 49.2 51.8 7.3
N 50.7 45.6 3.8
Q 48.6 33.8 3.1
Mean 50.4 47.8 5.7
SEM 4.9 9.0 1.5
Values are in µmol·FFM kg−1·h−1.
Table 3.9: Individual non-compartmental fluxes (Tyr samples at t=5 and 10
minutes discarded)
Subject Ra,Phe Ra,Tyr Phe→ Tyr
A 47.2 45.0 6.1
B 50.3 43.9 4.2
C 56.3 38.9 4.6
D 48.0 50.3 6.6
E 46.3 45.9 6.1
F 43.3 38.4 5.1
I 62.0 52.3 5.7
L 53.1 42.1 5.2
M 49.2 53.3 7.3
N 50.7 44.2 3.6
Q 48.6 35.6 3.1
Mean 50.4 44.5 5.2
SEM 4.9 5.7 1.3
Values are in µmol·FFM kg−1·h−1.
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3.2 Compartmental Analysis
3.2.1 The Four Compartments Model (Model 1)
The submodels provide a good fit of experimental data, shown in Figure 3.4.
In particular, the mean weighted residuals’ patterns confirmed by visual
inspection the goodness of the fit.
The population average upper and lower bounds of every parameter are
reported in Table 3.10, while the individual values are reported for every
submodel in tables 3.11, 3.13 (Model 1.a) and 3.12, 3.14 (Model 1.b). Due
to the large dimension of the data, every submodel is further divided in
tracer (tables 3.11 and 3.12) and tracee (tables 3.13 and 3.14) parameters.
All parameters were estimated with good precision, as the maximum CV%
is 41%.
Figure 3.4: Ability of Model 1 to fit data
Average Data (solid dots) vs. Average model fit (continuous line) in left
panels, average weighted residuals in right panels.
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Table 3.10: Model 1 parameters
Variable Unit Lower Bound Upper Bound
k01 min−1 0 0.051 ± 0.010
k02 min−1 0 0.019 ± 0.002
k03 min−1 0 0.079 ± 0.014
k04 min−1 0 0.017 ± 0.002
k12 min−1 0.017 ± 0.004 0.036 ± 0.006
k21 min−1 0.044 ± 0.007 0.095 ± 0.014
k31 min−1 0.0047 ± 0.0015
k34 min−1 0.017 ± 0.006 0.033 ± 0.007
k43 min−1 0.076 ± 0.026 0.155 ± 0.033
Q1
µmol 876 ± 196
µmol/FFM kg 16 ± 4
Q2
µmol 1095 ± 308 5503 ± 1919
µmol/FFM kg 19 ± 4 94 ± 17
Q3
µmol 475 ± 151
µmol/FFM kg 8 ± 3
Q4
µmol 1051 ± 330 4517 ± 1869
µmol/FFM kg 19 ± 6 77 ± 21
F01 µmol·FFM kg−1·h−1 0 46.4 ± 4.8
F02 µmol·FFM kg−1·h−1 0 105.4 ± 12.3
F03 µmol·FFM kg−1·h−1 0 38.4 ± 7.5
F04 µmol·FFM kg−1·h−1 0 76.1 ± 15.2
F12 µmol·FFM kg−1·h−1 40.8 ± 10.1 91.3 ± 14.2
F21 µmol·FFM kg−1·h−1 40.8 ± 10.1 87.2 ± 13.9
F31 µmol·FFM kg−1·h−1 4.1 ± 1.0
F34 µmol·FFM kg−1·h−1 38.3 ± 17.0 72.7 ± 22.2
F43 µmol·FFM kg−1·h−1 38.3 ± 17.0 76.8 ± 22.6
U1 µmol·FFM kg−1·h−1 0 50.2 ± 5.2
U2 µmol·FFM kg−1·h−1 0 109.5 ± 12.6
U3 µmol·FFM kg−1·h−1 0 34.3 ± 6.8
U4 µmol·FFM kg−1·h−1 0 72.0 ± 14.4
Values are expressed as Mean ± SEM
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Table 3.11: Model 1.a tracer parameters
Subj. Q1 Q3 k01 k03 k12 k21 k31 k34 k43
A Value 989 604 0.046 0.068 0.029 0.038 0.0052 0.027 0.051CV% 8 19 7 15 11 12 11 16 20
B Value 1137 364 0.035 0.083 0.038 0.042 0.0024 0.035 0.076CV% 4 18 4 14 6 8 9 12 18
C Value 1105 783 0.053 0.068 0.03 0.046 0.0053 0.024 0.057CV% 12 25 10 18 12 16 14 11 14
D Value 901 472 0.054 0.091 0.029 0.038 0.0057 0.03 0.062CV% 5 20 4 14 6 7 8 8 12
E Value 823 361 0.056 0.099 0.04 0.049 0.0053 0.033 0.075CV% 11 28 9 19 10 17 14 11 16
F Value 446 225 0.062 0.097 0.039 0.056 0.0057 0.044 0.145CV% 10 41 8 34 7 12 12 15 30
I Value 931 595 0.046 0.07 0.043 0.049 0.0046 0.041 0.09CV% 12 21 10 16 12 21 13 8 11
L Value 984 481 0.059 0.082 0.031 0.04 0.0045 0.027 0.051CV% 11 39 9 26 11 15 17 13 19
M Value 703 483 0.064 0.085 0.032 0.05 0.0072 0.028 0.067CV% 9 24 7 17 8 11 12 11 15
N Value 868 495 0.036 0.055 0.044 0.035 0.0024 0.038 0.09CV% 5 20 4 17 8 12 7 12 22
Q Value 746 360 0.053 0.072 0.037 0.039 0.0029 0.041 0.077CV% 7 22 6 17 8 12 9 9 19
Mean
Value 876 475 0.051 0.079 0.036 0.044 0.0047 0.033 0.076
CV% 9 25 7 19 9 13 11 12 18
SEM 196 151 0.01 0.014 0.006 0.007 0.0015 0.007 0.026
Values are in min−1 (kij), µmol (Qi). Precisions of estimated parameters
are expressed as CV% = 100 SD(pi,est)/pi,est, where CV is the coefficient of
variation and SD is the standard deviation.
3.2 Compartmental Analysis 49
Table 3.12: Model 1.b tracer parameters
Subj. Q1 Q3 k02 k04 k12 k21 k31 k34 k43
A Value 989 604 0.016 0.015 0.013 0.085 0.0052 0.012 0.119CV% 8 19 9 15 13 9 11 19 17
B Value 1137 364 0.017 0.018 0.021 0.077 0.0024 0.017 0.159CV% 4 18 5 11 8 6 9 15 15
C Value 1105 783 0.016 0.013 0.014 0.099 0.0053 0.011 0.126CV% 12 25 10 10 16 13 14 13 16
D Value 901 472 0.017 0.018 0.012 0.093 0.0057 0.012 0.153CV% 5 20 5 7 8 5 8 11 13
E Value 823 361 0.021 0.019 0.019 0.105 0.0053 0.014 0.174CV% 11 28 7 8 14 12 14 16 17
F Value 446 225 0.02 0.018 0.019 0.118 0.0057 0.026 0.241CV% 10 41 5 8 10 10 12 21 31
I Value 931 595 0.021 0.018 0.022 0.095 0.0046 0.023 0.16CV% 12 21 8 4 16 15 13 11 13
L Value 984 481 0.019 0.016 0.013 0.099 0.0045 0.01 0.133CV% 11 39 9 12 15 11 17 19 22
M Value 703 483 0.018 0.016 0.014 0.114 0.0072 0.012 0.152CV% 9 24 6 9 10 8 12 14 15
N Value 868 495 0.022 0.015 0.022 0.072 0.0024 0.024 0.146CV% 5 20 5 10 11 8 7 14 20
Q Value 746 360 0.021 0.02 0.015 0.092 0.0029 0.021 0.148CV% 7 22 6 7 11 8 9 13 17
Mean Value 876 475 0.019 0.017 0.017 0.095 0.0047 0.017 0.155CV% 9 25 7 9 12 10 11 15 18
SEM 196 151 0.002 0.002 0.004 0.014 0.0015 0.006 0.033
Values are in min−1 (kij), µmol (Qi). Precisions of estimated parameters
are expressed as CV% = 100 SD(pi,est)/pi,est, where CV is the coefficient of
variation and SD is the standard deviation.
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Table 3.13: Model 1.a tracee parameters
Subj. F01 F03 F12 F21 F31 F34 F43 Q1 Q2 Q3 Q4 U1 U3
A Value 42.3 37.6 35 35 4.7 28.6 28.6 15 20 9 18 47.1 32.9CV% 3 7 7 7 7 11 11 8 8 19 15 2 7
B Value 47 35.7 56.2 56.2 3.2 32.7 32.7 22 25 7 16 50.2 32.5CV% 1 7 5 5 7 13 13 4 4 18 13 1 7
C Value 51.2 47.1 45 45 5.1 39.3 39.3 16 25 12 27 56.4 41.9CV% 4 8 9 9 8 15 15 12 9 25 15 3 8
D Value 43.3 38.1 30.7 30.7 4.6 25.8 25.8 13 18 7 14 47.8 33.6CV% 2 7 4 4 7 13 13 5 5 20 12 2 7
E Value 42.4 32.9 37.3 37.3 4 25 25 13 16 6 13 46.5 28.8CV% 3 10 9 9 9 20 20 11 6 28 15 3 10
F Value 39.8 31.3 36.1 36.1 3.6 46.8 46.8 11 15 5 18 43.4 27.6CV% 3 9 7 7 9 23 23 10 5 41 12 2 9
I Value 56.6 55.3 61.1 61.1 5.7 70.9 70.9 21 24 13 29 62.3 49.6CV% 3 5 12 12 7 13 13 12 7 21 6 3 5
L Value 49.3 33.3 33.4 33.4 3.8 20.8 20.8 14 18 7 13 53 29.5CV% 3 13 9 9 13 26 26 11 8 39 24 3 14
M Value 44.2 40.1 34 34 5 31.5 31.5 12 18 8 19 49.2 35.1CV% 3 8 7 7 7 15 15 9 6 24 14 3 8
N Value 47.7 41.6 46.7 46.7 3.2 68.1 68.1 22 18 13 30 50.8 38.5CV% 1 5 8 8 5 10 10 5 4 20 8 1 5
Q Value 46.1 29.9 33.6 33.6 2.5 32 32 15 15 7 13 48.6 27.4CV% 2 6 7 7 6 11 11 7 5 22 7 2 6
Mean
Value 46.4 38.4 40.8 40.8 4.1 38.3 38.3 16 19 9 19 50.5 34.3
CV% 3 8 8 8 8 16 16 9 6 25 13 2 8
SEM 4.8 7.5 10.1 10.1 1 17 17 4 4 3 7 5.2 6.8
Values are in µmol·FFM kg−1·h−1 (Fij , Ui) or µmol/FFM kg (Qi). Preci-
sions of calculated variables are expressed as CV%, where CV is the coeffi-
cient of variation.
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Table 3.14: Model 1.b tracee parameters
Subj. F02 F04 F12 F21 F31 F34 F43 Q1 Q2 Q3 Q4 U2 U4
A Value 99.3 80.8 82.1 77.4 4.7 61.5 66.3 15 105 9 88 104 76.1CV% 5 9 4 4 7 8 8 8 11 19 17 5 9
B Value 89 71.2 106.4 103.2 3.2 65.2 68.4 22 86 7 66 92.2 68CV% 3 8 3 3 7 9 9 4 5 18 13 3 8
C Value 115.5 97.2 101.3 96.2 5.1 81.2 86.4 16 120 12 122 120.6 92.1CV% 6 6 5 5 8 11 11 12 12 25 10 6 6
D Value 110.7 87.7 78.6 74 4.6 59.4 64 13 109 7 81 115.2 83.2CV% 3 5 2 2 7 9 9 5 6 20 9 3 5
E Value 95.3 70.9 83.7 79.7 4 53.8 57.9 13 75 6 64 99.4 66.8CV% 6 7 5 5 9 14 14 11 11 28 11 6 7
F Value 87.7 49.7 79.6 75.9 3.6 74.4 78.1 11 71 5 47 91.3 46CV% 5 6 4 4 9 18 17 10 8 41 9 4 6
I Value 114.2 93.9 123.4 117.7 5.7 120.5 126.2 21 92 13 88 119.9 88.3CV% 7 3 6 6 7 10 10 12 11 21 4 7 3
L Value 127.4 80.7 86.5 82.7 3.8 50.3 54.1 14 114 7 82 131.2 76.9CV% 6 9 4 5 13 19 18 11 12 39 15 6 9
M Value 108 84.7 83.2 78.2 5 66.7 71.6 12 100 8 90 113 79.8CV% 4 6 4 4 7 11 11 9 8 24 11 4 6
N Value 99.5 65.2 97.5 94.4 3.2 106.6 109.7 22 75 13 74 102.6 62CV% 5 6 4 4 5 8 7 5 8 20 9 4 6
Q Value 112.9 55.5 82.2 79.7 2.5 59.5 62 15 88 7 47 115.3 53CV% 5 6 3 3 6 8 8 7 9 22 9 5 6
Mean
Value 105.4 76.1 91.3 87.2 4.1 72.7 76.8 16 94 9 77 109.5 72
CV% 5 6 4 4 8 11 11 9 9 25 11 5 6
SEM 12.3 15.2 14.2 13.9 1 22.2 22.6 4 17 3 21 12.6 14.4
Values are in µmol·FFM kg−1·h−1 (Fij , Ui) or µmol/FFM kg (Qi). Preci-
sions of calculated variables are expressed as CV%, where CV is the coeffi-
cient of variation.
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3.2.2 The Six Compartments Model (Model 2)
The model provides a good fit of experimental data, shown in Figure 3.5.
In particular, the mean weighted residuals’ patterns confirmed by visual
inspection the goodness of the fit.
The population average of every parameter is reported in Table 3.15, while
the single subject values are reported in tables 3.16, 3.17, 3.18 and 3.19. Due
to the large dimension of the data, the presentation of the results is divided
in tracer (tables 3.16 and 3.17) and tracee (tables 3.18 and 3.19) parameters.
All parameters were estimated with good precision, as the maximum CV%
is 27%.
Figure 3.5: Ability of Model 2 to fit data
Average Data (solid dots) vs. Average model fit (continuous line) in left
panels, average weighted residuals in right panels.
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Table 3.15: Model 2 parameters
Variable Unit Value
k02 min−1 0.020 ± 0.003
k04 min−1 0.017 ± 0.002
k12 min−1 0.026 ± 0.016
k15 min−1 1.012 ± 0.004
k21 min−1 0.165 ± 0.055
k34 min−1 0.017 ± 0.006
k36 min−1 1.016 ± 0.004
k43 min−1 0.135 ± 0.032
k51 min−1 0.032 ± 0.0001
k63 min−1 0.017 ± 0.00001
k65 min−1 0.285 ± 0.082
Q1
µmol 573 ± 165
µmol/FFM kg 10 ± 2
Q2
µmol 4459 ± 1867
µmol/FFM kg 75 ± 19
Q3
µmol 593 ± 195
µmol/FFM kg 10 ± 2
Q4
µmol 4806 ± 1976
µmol/FFM kg 82 ± 22
Q5
µmol 14 ± 4
µmol/FFM kg 0.24 ± 0.05
Q6
µmol 14 ± 4
µmol/FFM kg 0.24 ± 0.04
F02 µmol·FFM kg−1·h−1 89.5 ± 14.3
F04 µmol·FFM kg−1·h−1 79.6 ± 15.1
F12 µmol·FFM kg−1·h−1 102.7 ± 36.1
F15 µmol·FFM kg−1·h−1 14.8 ± 2.9
F21 µmol·FFM kg−1·h−1 98.7 ± 36.1
F34 µmol·FFM kg−1·h−1 77.7 ± 16.4
F36 µmol·FFM kg−1·h−1 14.4 ± 2.4
F43 µmol·FFM kg−1·h−1 81.7 ± 16.6
F51 µmol·FFM kg−1·h−1 18.9 ± 3.1
F63 µmol·FFM kg−1·h−1 10.3 ± 2.0
F65 µmol·FFM kg−1·h−1 4.0 ± 0.9
U2 µmol·FFM kg−1·h−1 93.5 ± 14.8
U4 µmol·FFM kg−1·h−1 75.6 ± 14.3
Values are expressed as Mean ± SEM
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Table 3.16: Model 2 tracer parameters (Part 1)
Subject k02 k04 k12 k15 k21 k34
A Value 0.017 0.015 0.016 1.010 0.120 0.012CV% 10 17 14 13 6 21
B Value 0.019 0.017 0.034 1.012 0.172 0.015CV% 10 20 17 13 9 27
C Value 0.017 0.013 0.015 1.016 0.120 0.012CV% 10 14 15 13 6 17
D Value 0.018 0.018 0.013 1.009 0.118 0.013CV% 8 6 11 13 4 10
E Value 0.022 0.018 0.021 1.010 0.138 0.016CV% 8 9 14 13 6 15
F Value 0.021 0.018 0.021 1.010 0.167 0.031CV% 7 9 13 13 6 20
I Value 0.023 0.017 0.048 1.022 0.282 0.020CV% 9 3 22 12 14 6
L Value 0.021 0.016 0.016 1.009 0.147 0.010CV% 10 13 17 13 7 17
M Value 0.019 0.016 0.015 1.008 0.145 0.014CV% 7 9 11 13 4 13
N Value 0.025 0.014 0.062 1.018 0.256 0.022CV% 8 10 19 13 13 14
Q Value 0.023 0.020 0.021 1.010 0.151 0.022CV% 9 8 16 13 7 15
Mean
Value 0.020 0.017 0.026 1.012 0.165 0.017
CV% 9 11 15 13 7 16
SEM 0.003 0.002 0.016 0.004 0.055 0.006
Values are in min−1 (kij). Precisions of estimated parameters are expressed
as CV% = 100 SD(pi,est)/pi,est, where CV is the coefficient of variation and
SD is the standard deviation.
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Table 3.17: Model 2 tracer parameters (Part 2)
Subject k36 k43 k51 k63 k65
A Value 1.015 0.104 0.032 0.017 0.293CV% 13 8 12 13 21
B Value 1.016 0.116 0.032 0.017 0.167CV% 13 10 13 13 21
C Value 1.022 0.106 0.031 0.017 0.275CV% 12 6 13 13 21
D Value 1.015 0.131 0.032 0.017 0.316CV% 13 4 13 13 21
E Value 1.013 0.117 0.032 0.017 0.336CV% 13 6 12 13 22
F Value 1.015 0.188 0.032 0.017 0.358CV% 13 12 12 13 22
I Value 1.023 0.187 0.031 0.017 0.366CV% 12 3 13 13 23
L Value 1.012 0.110 0.032 0.017 0.284CV% 13 6 12 13 22
M Value 1.011 0.154 0.032 0.017 0.399CV% 13 5 12 13 22
N Value 1.020 0.162 0.031 0.017 0.174CV% 13 8 13 13 20
Q Value 1.016 0.110 0.032 0.017 0.172CV% 13 7 12 13 20
Mean
Value 1.016 0.135 0.032 0.017 0.285
CV% 13 7 13 13 21
SEM 0.004 0.032 0.0001 0.00001 0.082
Values are in min−1 (kij). Precisions of estimated parameters are expressed
as CV% = 100 SD(pi,est)/pi,est, where CV is the coefficient of variation and
SD is the standard deviation.
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Table 3.18: Model 2 tracee parameters (Part 1)
Subject F02 F04 F12 F15 F21 F34 F36 F43 F51 F63 F65
A Value 88.1 83.9 82.9 15.9 78.3 65.8 15.9 70.4 20.6 11.3 4.6CV% 5 6 6 16 6 8 9 8 12 13 5
B Value 72.7 77.9 128.5 19.7 125.3 69.1 13.6 72.4 22.9 10.4 3.2CV% 5 8 9 15 9 11 10 10 13 13 6
C Value 108.9 101.9 99.6 19.5 94.3 93.1 20.8 98.3 24.8 15.5 5.3CV% 5 6 6 16 6 6 9 6 13 13 5
D Value 100.7 92.8 76.5 14.7 71.9 68.4 13.9 73.0 19.2 9.3 4.6CV% 4 3 4 17 4 4 9 4 13 13 3
E Value 85.7 80.4 82.1 13.3 77.6 68.6 14.8 73.0 17.7 10.4 4.4CV% 4 4 6 17 6 6 9 6 12 13 5
F Value 78.0 52.3 76.6 10.2 73.0 88.9 11.8 92.5 13.8 8.2 3.6CV% 4 4 5 17 6 12 9 12 12 13 5
I Value 82.6 91.6 176.3 14.0 171.2 106.3 15.0 111.3 19.1 9.9 5.0CV% 6 2 14 17 14 4 9 3 13 13 6
L Value 109.8 86.4 82.9 13.2 79.1 57.5 13.0 61.2 17.0 9.3 3.7CV% 6 5 6 16 7 6 9 6 12 13 7
M Value 99.3 84.4 80.2 11.8 75.5 71.2 12.9 75.8 16.4 8.2 4.7CV% 4 4 4 17 4 5 8 5 12 13 4
N Value 66.1 63.0 161.3 16.6 158.5 100.5 13.5 103.4 19.4 10.6 2.8CV% 5 4 13 15 13 8 10 8 13 13 5
Q Value 92.3 61.0 83.0 14.4 80.5 65.4 12.7 67.8 16.8 10.3 2.4CV% 5 4 7 15 7 7 10 7 12 13 4
Mean
Mean 89.5 79.6 102.7 14.8 98.7 77.7 14.4 81.7 18.9 10.3 4.0
CV% 5 4 7 16 7 7 9 7 13 13 5
SEM 14.3 15.1 36.1 2.9 36.1 16.4 2.4 16.6 3.1 2.0 0.9
Values are in µmol·FFM kg−1·h−1 (Fij). Precisions of calculated variables
are expressed as CV%, where CV is the coefficient of variation.
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Table 3.19: Model 2 tracee parameters (Part 2)
Subject Q1 Q2 Q3 Q4 Q5 Q6 U2 U4
A Value 11 84 11 94 0.26 0.26 92.7 79.3CV% 0 10 0 15 20 15 4 7
B Value 12 63 10 78 0.32 0.22 75.9 74.6CV% 0 10 0 19 19 16 5 8
C Value 13 110 15 129 0.32 0.34 114.2 96.6CV% 0 11 0 12 20 16 5 6
D Value 10 95 9 85 0.24 0.23 105.3 88.2CV% 0 9 0 7 21 15 4 3
E Value 9 66 10 74 0.22 0.24 90.1 76.0CV% 0 10 0 10 21 15 4 4
F Value 7 61 8 48 0.17 0.19 81.7 48.7CV% 0 9 0 10 21 15 4 5
I Value 10 61 10 88 0.23 0.24 87.6 86.6CV% 0 12 0 3 21 15 6 2
L Value 9 89 9 91 0.22 0.21 113.6 82.6CV% 0 13 0 13 21 16 6 5
M Value 9 88 8 87 0.19 0.21 104.0 79.8CV% 0 8 0 9 22 15 3 4
N Value 10 43 11 77 0.27 0.22 69.0 60.2CV% 0 10 0 8 19 16 5 4
Q Value 9 67 10 50 0.24 0.21 94.7 58.6CV% 0 11 0 10 19 16 5 4
Mean
Mean 10 75 10 82 0.24 0.24 93.5 75.6
CV% 0 10 0 11 20 16 5 5
SEM 2 19 2 22 0.05 0.04 14.8 14.3
Values are in µmol/FFM kg (Qi) or µmol·FFM kg−1·h−1 (Ui) . Precisions
of calculated variables are expressed as CV%, where CV is the coefficient of
variation.

Chapter 4
Discussion and validation
4.1 The Four Compartments Model (Model 1)
4.1.1 Model overview
The 4 compartments proposed model is not a priori uniquely identifiable,
meaning that its 9 kij ’s and 2 Qi’s cannot be uniquely determined from the
data. This is due to the fact that since protein synthesis and breakdown take
place in all tissues, it is not possible to exclude a priori the presence of any
of the irreversible losses (k0i) and productions (Ui) in both compartments of
Phe and Tyr kinetics. Moreover, it is not possible to establish constraints
between the parameters, once we come up with the physiological meaning
of every compartment. In fact, since we assume that both compartments
1 and 3 represent the plasma + fast exchanging tissues pool (for Phe and
Tyr, respectively), we must assume that some Phe or Tyr is being disposed
towards protein synthesis or oxidation (in the case of Tyr). Same fact holds
for compartments 2 and 4, that represent the slow tissues pool (for Phe
and Tyr, respectively). Although the model is not uniquely identifiable,
we can estimate uniquely only some combinations of the rate constants.
Hence, only the kinetic parameters that can be expressed as a function of the
observational parameters can be calculated uniquely: Q1, Q3 and k31. For
the other parameters, only the interval of admissible values can be obtained,
basing the analysis on the use of submodels (Model 1.a and Model 1.b) [19,
10]. Adopting this technique, each submodel is both a priori and a posteriori
identifiable, meaning that all of its parameters can be estimated with very
good precision from the experimental data (CV%’s never exceed 41%). The
estimations from each submodel constitute the range of admissible values for
every parameter of the original system model.
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4.1.2 Model development and rationale
The model proposed has the least number of compartments required to ac-
count for the dynamic properties of our data and to be consistent with known
physiology. The disappearance of both tracers in plasma can be described
by a two-term exponential equation (sections 2.2 and 3.1), indicating that
there is at least one compartment equilibrating the plasma pool over the
studied period for each amino acid [36]. One may argue that this compart-
ment should be the intracellular pool alone, where the conversion from Phe
to Tyr is known to be taking place [26]. Even though this may seem the
most physiologically attractive option (Model 7, Figure 4.2), the attempt to
fit experimental data to a model with such structure failed to describe the
appearance in plasma of Tyr as Phe’s metabolite (Figure 4.1). This failure
to fit data with that simple model structure suggests that the exchanges be-
tween plasma and the intracellular pool (in which the hydroxylation process
is happening) might be so fast that it is not possible to model the pools as
separate compartments. This appears to be consistent with the studies of
Thompson [35] and Layman [23], where it is also speculated that the pool for
Phe hydroxylation might mix extremely rapidly with the body pool. There-
fore, it was chosen to locate the site of conversion from Phe to Tyr directly
in the accessible compartments (1 and 3), thus merging plasma and fast ex-
changing tissues in one single pool. In the spirit of such consideration, the
most logical (and physiologically based) suggestion for the other compart-
ment to be equilibrating with plasma (and fast tissues all together, at this
point) appears to be the slow exchanging tissues compartment (compart-
ments 2 and 4, Figure 2.1).
Figure 4.1: Failure to describe L-[ring-13C6]-Tyr data with Model 7
Data (solid dots) vs. model fit (continuous line) in left panel, weighted
residuals in right panel (from Subject A).
Keeping in mind that this model structure has a clear physiological rel-
evance, the issue of the a priori identifiability of the tracer model is not
easy to overcome. As already mentioned before, it is not easy to establish a
4.1 The Four Compartments Model (Model 1) 61
Figure 4.2: Model 7 structure
The circles indicate compartments representing kinetically distinct pools of
Phenylalanine and Tyrosine and the arrows between them the intercompart-
mental fluxes. kij (per minute) are the transfer rate constants of flux from
compartment j to compartment i. Large arrows denote Phe (solid arrow)
and Tyr (open arrow) tracer inputs. TTRi measurements are indicated by
dashed lines ending with solid (from Phe tracer input) or open (from Tyr
tracer input) circle, respectively.
constraint for the two irreversible losses (k01, k02 and k03, k04) in the com-
partments of each amino acid, as it would have the effect of making the
tracer model uniquely identifiable. Additional complications arise from the
assumption that compartments 1 and 3 merge two physiologically known
to be distinct pools [26], so that using constraints such as k01 = k02 and
k03 = k04 would be difficult to justify. Based on these considerations, it was
decided not to use any constraints of such kind and to proceed by identify-
ing bounds for the parameters of this non-uniquely identifiable model. This
approach is meant to give the reader a less biased overview of the underlying
physiological system, by making the least number of possible assumptions.
Finally, just as one cannot exclude a priori the existence of the irreversible
losses (k0i), it is not trivial to establish the site from which the amino acids
are entering the system by protein breakdown. In fact, one would probably
observe protein catabolism in both slow and fast exchanging tissues during
the study period. Therefore, it was chosen to break the main model into
submodels once again, in order to establish the upper and lower bounds for
the fluxes of interest in the tracee model.
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4.1.3 Model features
An important feature of the model is that the hydroxylation flux (F31) is
uniquely identifiable from the dataset and is estimated with very high pre-
cision (averaging a CV% of 8% for the 11 subjects, tables 3.13 and 3.14).
In general, one would expect the variables Ra,Phe, Ra,Tyr and Phe → Tyr
of the non-compartmental analysis [36] to match the variables U1, U3 + F31
and F31 (respectively) provided by Model 1.a of the compartmental analysis.
This is indeed verified when Ra,Phe, Ra,Tyr and Phe → Tyr are obtained
from AUCs from Model 1 fitted curves. Nevertheless, these values show dif-
ferences with the pure non-compartmental analysis (sections 2.2 and 3.1), as
resumed in Table 4.1.
Table 4.1: Comparison for relevant physiological variables as computed by
non-compartmental approaches and the minimal compartmental approach
Approach AUCPhe+6 AUCTyr+4 AUCTyr+6 Ra,Phe Ra,Tyr Phe→ Tyr
NC (Complete) Mean 6.582 0.477 0.769 50.4 47.8 5.7SEM 1.593 0.150 0.181 4.9 9.0 1.5
NC (Partial) Mean 6.582 0.501 0.759 50.4 44.5 5.2SEM 1.593 0.140 0.209 4.9 5.7 1.3
C (Model 1) Mean 6.577 0.586 0.696 50.5 38.4 4.1SEM 1.662 0.167 0.175 5.2 7.5 1.0
Values are in min (AUCAA+i), µmol·FFM kg−1·h−1 (Ra,AA and Phe →
Tyr). NC (Complete) column refers to the non-compartimental approach
when all data points are considered, while NC (Partial) column represents
the same approach when samples at t=5 and 10 minutes are discarded from
Tyr curves. C (Model 1) column represents the computation of the variables
from Model 1 fitted curves.
As one can see, Ra,Phe computed from Model 1 curves remains perfectly
consistent with the non-compartmental approach. On the other side, Ra,Tyr
shows a higher variability, depending on the approach adopted. In fact,
the values computed with non-compartmental approaches are greater than
their compartmental counterpart. Such observation is easily understandable
by observing the comparison between the average fitted curves in Figure
4.3 (L-[ring-2H4]-Tyr, left panel): the TTR values at t=0 min provided by
Model 1 are consistently higher than those given by the non-compartmental
approaches (even when the first two samples are not considered).
The differences in the TTR values at t=0 min imply a systematically
higher value for AUCTyr+4 from Model 1 (0.586 ± 0.167 min, mean ± SEM)
when compared to the non-compartmental approaches (0.477 ± 0.150 and
0.501 ± 0.586 min, respectively, mean ± SEM), resulting in a lower value
for Ra,Tyr from Model 1 (38.4 ± 7.5 µmol·FFM kg−1·h−1, mean ± SEM)
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Figure 4.3: Comparison between non-compartmental and compartmental
(Model 1) fitted curves
Average Data (solid dots) vs. Average model fit (continuous line) in left
panels, average weighted residuals in right panels. Continuous blue line
represents non-compartmental approach when all data points are considered,
while the continuous red line represents the same approach when samples at
t=5 and 10 minutes of Tyr curves are discarded. Continuous black line
represents Model 1.
when compared to the NC approaches (47.8 ± 9.0 and 44.5 ± 5.7 µmol·FFM
kg−1·h−1, respectively, mean ± SEM). Therefore, the effect of excluding Tyr
samples at t=5 and 10 minutes from the analysis is not so determinant in
terms of variability for Ra,Tyr, as one might expect; instead, it is the use
of a compartmental approach that marks the biggest separation. Indeed,
the Model 1 fitted curves are generated from kinetic parameters that use
information from both L-[ring-2H4]-Tyr and L-[ring-
13C6]-Tyr TTR curves
and are therefore more physiologically relevant than the non-compartmental
curves. Finally, the differences existing in the computed Phe→ Tyr conver-
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sion rates appear to be mainly due to the value of Ra,Tyr as it is entered in
equation (2.14). Nevertheless, by observing the intervals in terms of mean
± SEM provided by the three approaches one can see that they are overlap-
ping, meaning consistency between the approaches.
At this point, it is interesting to compare the net PB (Protein Breakdown)
flux of Model 1 (F31) to the one obtained by Engelen et al. [18] with primed
constant infusion of the isotopes L-[ring-2H5]-Phe and L-[ring-
2H2]-Tyr in
11 healthy male subjects in the postabsorptive state (Table 4.2). The above
mentioned study recorded a value of 4.6 ± 0.3 µmol·FFM kg−1·h−1 (mean ±
SEM) for the net PB flux, which is comparable to the 4.1 ± 1.0 µmol·FFM
kg−1·h−1 (mean ± SEM) predicted by Model 1. In addition, the values of
PB (53.0 ± 2.7 µmol·FFM kg−1·h−1 (mean ± SEM)) and PS (Protein Syn-
thesis) (48.5 ± 2.5 µmol·FFM kg−1·h−1 (mean ± SEM)) appear quite close
to the those given by Model 1.a (50.5 ± 5.2 µmol·FFM kg−1·h−1 (mean ±
SEM) and 46.4 ± 4.8 µmol·FFM kg−1·h−1 (mean ± SEM), respectively).
These observations appear to confirm the quality of the variables as they
are gleaned from the compartmental analysis in the present pulse protocol
study.
Table 4.2: Comparison between variables gleaned from primed constant in-
fusion (non-compartmental) [18] and pulse (compartmental) data
Primed Const. Infusion (NC) Pulse (C, Model 1.a)
PS 48.5 ± 2.5 46.4 ± 4.8
PB 53.0 ± 2.7 50.5 ± 5.2
Net PB 4.6 ± 0.3 4.1 ± 1.0
Values are in µmol·FFM kg−1·h−1 (mean ± SEM). PS, PB stand for Protein
Synthesis and Protein Breakdown, respectively. Data in the Primed Const.
Infusion (NC) column were obtained with NC approach calculations in 11
male healthy subjects (postabsorptive state) by Engelen et al. [18] from
primed constant infusion of isotopes L-[ring-2H5]-Phe and L-[ring-
2H2]-Tyr.
Data in the Pulse (C, Model 1.a) column were obtained in the present study
by compartmental analysis for Model 1.a.
As mentioned in Section 2.3, another feature of the model is it underlines
an important problem, namely: Tyr tracers might suffer from a mixing pool
issue in the initial minutes after the pulse injection [21, 27]. Having a closer
look at the plots displayed in Figure 3.4, one may observe that the samples
at t=5 and 10 minutes are discarded from the analysis in the two Tyr curves.
When it was attempted to fit the data (including these first two samples of
the Tyr curves) to the model, it was recorded a trending underestimation
of the L-[ring-2H4]-Tyr data in the first 3-4 samples (Figure 4.4), and that
observation led to inspect the physiological feasibility of the accessible es-
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timated pools: while Q1 (967.64 ± 150.97 µmol) was estimated to be well
above the threshold (approx. 136 µmol) for the minimum possible sampling
plasma pool for Phe in every subject, Q3 (124.62 ± 58.84 µmol) and its in-
dividual values for the majority of the subjects were estimated to be below
the threshold (approx. 139 µmol) for the minimum possible sampling pool
for Tyr, which leads to a physiologically infeasible system. The above con-
siderations suggested that the first two Tyr samples might have been biased
by the mixing issue related to the Tyr pool [21, 27], and as a result it was
decided to discard those samples from the analysis.
Figure 4.4: Systematic underestimation of the first samples in L-[ring-2H4]-
Tyr data when samples at t=5 and 10 minutes are considered
Average Data (solid dots) vs. Average model fit (continuous line) in left
panel, average weighted residuals in right panel.
4.1.4 Physiological evidence
As far as the uniquely estimable pools (Q1 and Q3) are concerned, the model
allows for some interesting observations. It was already pointed out in Sec-
tion 4.1.3 that if one considers the average [Phe]plasma (41 µmol/L), one can
estimate the plasma Phe pool to be approximately 136 µmol (assuming the
plasma volume to be a standard 3.3 L). Additionally, if one assumes Phe’s
concentration in the liver, which is responsible for the most part of the hy-
droxylation process occurring in the body, to be approximately double the
concentration recorded in plasma, as supported by data in pigs (unpublished,
courtesy of CTRAL), we would roughly have [Phe]liver = 82 µmol/L. Assum-
ing then a standard liver volume of 1.5 L [34], that allows to estimate the Phe
mass in the liver to be around 123 µmol. In that sense, the sum of plasma
and liver pools of Phe could be estimated to be roughly 259 µmol. At the
same time, Model 1 estimates the average value for Q1 to be approximately
876 µmol which would leave about 617 µmol of free Phe unassigned. The
remaining portion of this big pool is likely to be constituted by extracellular
fluids (437 µmol, if we do not account for the already considered plasma) and
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other tissues in fast exchange with plasma (occupying the about remaining
180 µmol).
Using similar assumptions, we can estimate the plasma Tyr pool to be ap-
proximately 139 µmol (starting from an average [Tyr]plasma(42 µmol/L)).
Assuming then [Tyr]liver = 84 µmol/L, one can estimate the Tyr mass in
the liver to be around 126 µmol, thus making the sum of plasma and liver
pools of Tyr roughly 256 µmol. At the same time, the model estimates the
average value for Q3 to be approximately 475 µmol, which would leave about
210 µmol of free Tyr that is not trivial to assign. The remaining part of this
pool is likely to be comprised mainly by a portion extracellular fluids and
tissues in fast exchange with plasma. These considerations seem to confirm
the physiological feasibility of the uniquely estimable pools provided by the
model, given the fact that the concentrations of the two amino acids in the
liver are unknown for the study subjects and may differ significantly from
what is observed in pigs. It is interesting to notice how even though Q1 and
Q3 are likely representative of analogous portions of the whole body and
although the plasma concentrations of the two amino acids as an average are
quite similar, the model estimates the two pools quite differently. This is
likely to result from a faster Phe exchange with a larger portion of the body
fluids and tissues compared to that of Tyr. It would be intriguing to test the
model on Phe and Tyr tracer data obtained in humans either by pulse (with
a more packed sampling scheme in the first 10 minutes) or by continuous
infusion. In the latest case in particular, the mixing pool issue of Tyr for the
first samples should not be present because the isotopic equilibrium would
be achieved sometime during the study period: if the pool sizes of Q1 and
Q3 would show a similar trend, then the aforementioned hypothesis would
be empirically verified.
As far as the non-uniquely identifiable pools are concerned (Q2 and Q4) we
can only provide the interval of validity of the masses of free Phe and Tyr
they contain. One can notice how in both cases and for the average esti-
mations on the population, the averages of the estimated upper and lower
bounds (56.7 µmol/FFM kg for Q2 and 48.1 µmol/FFM kg for Q4, which
should give the idea of the pools in a midway situation between the two
limit case scenarios of models 1.a and 1.b) identify pools much bigger than
the uniquely identifiable Q1 (15.7 µmol/FFM kg) and Q3 (8.5 µmol/FFM
kg). This observation appears to be consistent with the assumption of ap-
pointing compartments 2 and 4 to tissues in slow exchange with plasma and
fast tissues, since these would find their counterpart mainly in the muscles,
physiologically known to be a much bigger pool than the content of com-
partments 1 and 3.
Another unique feature of the compartmental analysis is that we have two
possible protein synthesis rates; the rate into the fast exchanging pool which
could be the fast turnover protein and the rate into the slow exchanging
pools. Because the model is not uniquely identifiable, only upper and lower
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limits are provided. Nevertheless, Model 1.b is likely to better represent the
changes in protein synthesis and breakdown in tissues like muscle. In fact,
being the subjects of the study in postabsorptive state, in order to ensure
the protection from degradation of the essential amino acids, the maximal
activities of the enzymes responsible for the degradation of the amino acids
in the liver are low, which could be translated in very limited or negligible
amounts for protein breakdown/synthesis fluxes (U1, U3, F01 and F03) for
compartments 1 and 3 of Model 1. This hypothesis was later verified through
the development of Model 2, as described in Section 4.2.6.
4.1.5 Consistency with the literature
The average endogenous productions (tables 3.13 and 3.14), entering the
tracee system (U1, U2, U3 and U4), i.e. free Phe and Tyr coming from pro-
tein catabolism in the two limit cases provided by the two submodels (Figure
2.2) can be used to quantify the ratio PtPp , which is the molar ratio of the
fluxes of Tyr and Phe arising from protein catabolism. Animal studies [29] in
the past estimated this ratio from protein composition to be 0.73 and a study
of Thompson et al. [35] recorded a ratio of 0.76 in human subjects with a
Phe-based non-compartmental model. In the case of Model 1.a, where both
the endogenous productions and the disposals are located in the plasma +
fast tissues pools (compartments 1 and 3), average estimated values of 50.5 ±
5.2 µmol·FFM kg−1·h−1 (mean ± SEM) were recorded for Phe entering the
system from protein breakdown (U1) and of 34.3 ± 6.8 µmol·FFM kg−1·h−1
(mean ± SEM) for Tyr entering the system by the same process (U3), thus
returning a value of PtPp of 0.68. In the case of Model 1.b, where both the en-
dogenous productions and the disposals are located in the slow tissues pools
(compartments 2 and 4), average estimated values of 109.5 ± 12.6 µmol·FFM
kg−1·h−1 (mean ± SEM) were recorded for Phe entering the system from
protein breakdown (U2) and of 72.0 ± 14.4 µmol·FFM kg−1·h−1 (mean ±
SEM) for Tyr entering the system by the same process (U4), thus returning
a value of PtPp of 0.66. Keeping in mind that the most likely physiological
situation might be the one in which both fast and slow tissues have pro-
tein breakdown happening, the limit cases of the molar ratio PtPp recorded by
Model 1 in the two scenarios are consistent with previously published results.
The two recorded molar ratios in the two limit scenarios displayed by the
here presented compartmental model (0.68 and 0.66, respectively for Model
1.a and 1.b) appear to be consistent with the observations of Matthews [26],
where it is reported that the expected rate of Tyr from protein breakdown
to be ∼0.60 that of Phe.
Furthermore, the study performed by Cortiella et al. [14] with a non com-
partmental approach in the postabsorptive state reported that approximately
14% of Tyr flux is derived from Phe hydroxylation, while the rate of Phe
that gets hydroxylated is approximately 11%. If one considers Model 1.a,
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the scenario that is closer in terms of structural similarities to the non-
compartmental approach, one would notice that the submodel reports that
approximately 12% of Tyr flux is derived from Phe hydroxylation, while
the rate of Phe that gets hydroxylated is approximately 8%. This shows
how with Model 1.a, because of the structural similarities with the non-
compartmental approach, we get estimates somehow consistent with those
obtained through non-compartmental approaches published in the literature,
with rates reported by compartmental analysis systematically slightly lower,
but with the benefit of a deeper structural insight. To be fair, all previously
published models could not glean the actual rates of protein breakdown in
the slow exchanging tissues, which are likely to better represent the whole
body protein physiology than the plasma rates of appearance, so that mak-
ing a comparison is not possible. For this reason, it is important to remark
how by choosing a model structure (Model 1.a) in which the endogenous
productions are located in the accessible compartments, the obtained values
are somehow consistent with values published in the literature, even though
Model 1.b is would probably better describe the actual kinetics of Phe-Tyr
metabolism in the postabsorptive state. The validation of Model 2 appears
to back up this hypothesis, as described in Section 4.2.6.
4.2 The Six Compartments Model (Model 2)
4.2.1 Model overview
The 6 compartments proposed model is a priori uniquely identifiable, mean-
ing that its 11 kij ’s can be uniquely determined from the data. Since samples
at t=5 and 10 minutes of Tyr curves were not considered and the model struc-
ture is more complex than Model 1 (accounting for 2 compartments more),
the accessible pool sizes Q1 and Q3 were calculated a priori, starting from
the fat-free mass (FFM) and plasma concentrations of Phe and Tyr of ev-
ery subject, as described in Section 2.3.2. Furthermore, maximum likelihood
(ML) estimation of some of the unknown parameters (k15, k36, k51 and k63)
was not possible and therefore maximum a priori (MAP) estimation was
used for such kinetic parameters.
The aim of this model is to overcome the identifiability issue provided by the
previously described four compartments model (Model 1), in order to pro-
vide a more detailed and complete picture of Phe-Tyr metabolism kinetics.
The model allows the accurate description of all unknown kinetic parame-
ters (as CV%’s do not exceed 27%) and was later validated by simulating
a continuous infusion experiment previously performed in pigs on the mean
human subject with it.
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4.2.2 Model development and rationale
It was already mentioned how 2 is the minimum number of compartments
per amino acid that allows the assessment of Phe-Tyr kinetics. Nevertheless,
merging the plasma compartments and those responsible for the hydroxyla-
tion process (fast exchanging tissues) leads to unidentifiability of the minimal
model structure because of the reasons that were presented in Section 4.1.1.
In the six compartments model (Model 2) here discussed, protein breakdown
and synthesis of Phe and Tyr in the sites responsible for the conversion (com-
partments 5 and 6) were assumed to be negligible, so as Tyr oxidation was.
The reason for such choice is to be found in CTRAL’s unpublished data
from a pig study, obtained by using a continuous infusion protocol. In fact,
taking a look at Table 4.3 that resumes this study, one can see how the TTRLTTRP
(where subscripts L and P stand for liver and plasma, respectively) ratio of
Phe at the steady state is close to 1, while the TTRLTTRP ratio of Tyr in the same
condition is higher than that value.
Table 4.3: Statistics of TTRLTTRP ratio in CTRAL’s unpublished pig study data
TTRL
TTRP
Phe 0.98 ± 0.26
Tyr 2.70 ± 1.22
Values are Mean ± SEM and were calculated at the steady state with a
constant infusion protocol
These data suggest that free Phe in plasma and liver (the latest being
the site mainly responsible for hydroxylation [26]) might be able to achieve
isotopic equilibrium at the steady state, meaning that from none of these
compartments there are endogenous productions entering the system. At
the same time, these data hint how between free Tyr in liver and plasma
there is no isotopic equilibrium, but this is due to the portion of Tyr that
is converted from Phe in the liver. In fact, being the subjects of the study
in postabsorptive state, in order to ensure the protection from degradation
of the essential amino acids, the maximal activities of the enzymes respon-
sible for the degradation of the amino acids in the liver are known to be
low. Because protein breakdown of Phe in the liver appears to be negligi-
ble, it is reasonable to assume that also protein breakdown and oxidation
of Tyr can be overlooked. These informations were translated to Model 2
structure: compartments 1 and 3 are therefore representative of plasma and
EC fluid, physiologically unable to breakdown or synthetize proteins [26];
compartments 5 and 6 represent the IC portion of tissues responsible for the
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hydroxylation process, in which protein breakdown and synthesis fluxes are
assumed to be negligible.
Because of these physiologically based assumptions, the entering site (via
protein breakdown) in the model for free Phe and Tyr are compartments
2 and 4, respectively (U2 and U4). Similarly, the protein synthesis process
(with Tyr oxidation, for Compartment 4) is assumed to take place in the
same two compartments (F02 and F04). These compartments represent the
IC portion of tissues exchanging with a slower kinetics with the accessible
EC pools (compartments 1 and 3).
4.2.3 Model features
As already pointed out, the key feature of Model 2 is that every unknown
parameter is uniquely identifiable from the dataset, once the previously men-
tioned assumptions are made. Furthermore, every parameter is estimated
with very high precision (maximum CV% is 27%), also due to the use of
MAP estimation for some of the unknown parameters (k15, k36, k51 and k63).
The hydroxylation flux (F65) of Model 2, assumes a value (4.0± 0.9 µmol·FFM
kg−1·h−1, mean ± SEM) in line to the one (F31) estimated by Model 1 (4.1
± 1.0 µmol·FFM kg−1·h−1, mean ± SEM). This fact somehow appears to
confirm the physiological feasibility of the structural assumptions made, even
more when we consider what the possible consequences of moving the en-
dogenous productions (U5, U6) and the disposals (k05, k06) to the compart-
ments involved in the hydroxylation process would be: F65 equal to 59.3 ±
20.3 µmol·FFM kg−1·h−1 (mean ± SEM), which would be much higher than
Model 1 results and the conversion rates present in the literature [26, 18].
Moreover, arguably the most innovative feature of Model 2 is that it allows
for the assessment of the actual protein breakdown rate of Phe in tissues,
rather than just an indication of it, as the Ra,Phe provided by the non-
compartmental approaches does. In fact, Ra,Phe measures only a portion of
the entire breakdown rate of Phe in tissues and the assessment of such quan-
tity is not possible with non-compartmental approaches. Therefore, it is not
possible to make a comparison with values provided by the literature either.
Nevertheless, it is interesting to notice how the PB rate in tissues (U2) pro-
vided by Model 2 is 93.5 ± 14.8 µmol·FFM kg−1·h−1 (mean ± SEM), which
is almost as double as the Ra,Phe calculated from the L-[ring-13C6]-Phe curve
(Model 1 fit, Table 4.1). This is something physiologically expected, because
of the aforementioned reasons.
4.2.4 Physiological evidence
Estimating a priori the accessible EC pools (Q1 and Q3), allows to identify
all the remaining ones (Q2, Q4, Q5 and Q6) as IC pools by exclusion. This
appears to strengthen the physiological relevance of the protein breakdown
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and synthesis rates from Phe (U2 and F02) as they are provided by Model 2.
As far as the estimated pools are concerned, the model allows for some inter-
esting observations. Q2 and Q4 are higher (75 ± 19 and 82 ± 22 µmol/FFM
kg, mean ± SEM, respectively) than their EC counterparts Q1 and Q3 (both
10 ± 2 ± µmol/FFM kg, mean ± SEM). This seems to be consistent with
the interpretation previously given to the slow tissues compartments of the
model: in fact, if we assume that compartments 2 and 4 represent mainly
muscular tissue, then this big difference is feasible, because the concentra-
tions of Phe and Tyr in muscle are likely to be higher than those in plasma
(Table 1.2), along with the muscles being a very large portion of the body.
Similarly, it is interesting to have a look (Table 3.15) at the estimated values
for Q5 and Q6: these pools are considerably small in size (0.24 ± 0.05 and
0.24 ± 0.04 µmol/FFM kg, mean ± SEM, respectively), probably because
only a coherently small portion of the liver is involved in the Phe to Tyr
conversion.
As far as the gleaned fluxes are concerned, the model allows for some further
interesting observations. First of all, looking at the average values for F15,
F36, F51 and F63 (Table 3.15), one can see how the EC pools (compartments
1 and 3) exchange with the IC pools involved in the hydroxylation process
(compartments 5 and 6) with a very fast kinetics, especially if the sizes of
these compartments are considered. In fact, looking at the average fractional
transfer rates (Table 3.15) k15, k36, k51 and k63, one can see how the pools
responsible for hydroxylation mix extremely rapidly with the EC pools. This
appears to be consistent with the studies of Thompson [35], Layman [23] and
what was observed in the development of Model 1: the exchanges between
these pools are so rapid that it is particularly complicated to model them
as separate entities. On the other end, if one observes the average fluxes
F12, F21, F34 and F43 (Table 3.15), it is possible to see how even though
these are higher than F15, F36, F51 and F63, the pools involved (Q1, Q2, Q3
and Q4) are in general way bigger in size than Q1, Q3, Q5 and Q6, thus
denoting a lower specific activity. Therefore, this observation is consistent
with the interpretation that was given to compartments 2 and 4: they are
representative of a very large IC portion of tissues in slow exchange with the
EC pools and the sites responsible for hydroxylation of Phe.
4.2.5 Consistency with the literature
The average endogenous productions (Table 3.15) entering the tracee system
(U2 and U4), i.e. free Phe and Tyr coming from protein catabolism in slow
tissues, can be used to quantify the ratio PtPp , which is the molar ratio of
the fluxes of Tyr and Phe arising from protein catabolism. It was already
mentioned in Section 4.1.5 how animal studies [29] in the past estimated
this ratio from protein composition to be 0.73, while a study of Thompson
et al. [35] recored a ratio of 0.76 in human subjects with a Phe-based non-
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compartmental model. In the case of Model 2, average estimated values of
93.5 ± 14.8 µmol·FFM kg−1·h−1 (mean ± SEM) for Phe entering the system
from protein breakdown (U2) and of 75.6 ± 14.3 µmol·FFM kg−1·h−1 (mean
± SEM) for Tyr entering the system by the same process (U4) were recorded,
thus returning a value of PtPp of 0.81. Therefore, the molar ratio
Pt
Pp
recorded
by Model 2 is somehow consistent with the previously published results.
Since all models regarding Phe-Tyr metabolism present in the literature are
based on non-compartmental approaches, it is not possible to make any
further comparisons similarly to what was done for Model 1.a. Nevertheless,
the value of the hydroxylation flux (F65, 4.0 ± 0.9 µmol·FFM kg−1·h−1,
mean ± SEM) provided by Model 2 appears to be quite consistent with the
results of Engelen et al. [18] in a similar study group obtained with a primed
constant infusion protocol (4.6 ± 0.3 µmol·FFM kg−1·h−1, mean ± SEM).
4.2.6 In silico validation
The average estimated tracer parameters shown in Table 3.15 were used to
validate Model 2 through the simulation of a previously performed experi-
ment in pigs by the CTRAL. The original pigs experiment used a continuous
infusion protocol of the stable isotopes L-[ring-13C6]-Phe and L-[3,3-D2]-Tyr.
The study involved 21 pigs and the infusion rates for the isotopes were of
56.6 ± 1.7 nmol·BW kg−1·min−1 (mean ± SEM, L-[ring-13C6]-Phe) and 53.1
± 2.3 nmol·BW kg−1·min−1 (mean ± SEM, L-[3,3-D2]-Tyr). The average
infusion rate of every stable isotope solution was proportioned to the mean
human subject body weight (85.9 BW kg) and used as input in the simulation
software SAAM II (version 2.2.1), together with the average kinetic param-
eters shown in tables 3.15. At the steady state, TTRs in compartments 1,
3, 5 and 6 were assessed (TTR1, TTR3, TTR5 and TTR6, respectively) and
TTR5
TTR1
, TTR6TTR3 were computed. These ratios were later compared to the
TTRL
TTRP
ratios of Phe and Tyr found in pigs. The comparison is resumed in Table
4.4.
Table 4.4: Comparison between real pig and human simulated data (mean
subject, Model 2)
Phe Tyr
TTRL
TTRP
TTR5
TTR1
TTRL
TTRP
TTR6
TTR3
(Pig) (Human) (Pig) (Human)
0.98 ± 0.26 1 2.70 ± 1.22 3.49
Values are adimensional (ratio), mean ± SEM in the TTRLTTRP columns
As one can notice, the values obtained with the in silico simulation are
quite similar to the ones provided by the pig study, if we account for the
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possible interspecies differences existing. The simulation appears to confirm
the validity of the structural assumptions made in the design phase, together
with the physiological relevance of the model. The fact that at the steady
state real pig and simulated human data show good consistency, suggests
that compartments 5 and 6 of the model might be well representative of the
IC portion of the liver. Furthermore, these results appear to confirm how the
scenario provided by Model 1.b might be the most physiologically relevant
in Model 1, given the similar structural assumptions made.

Chapter 5
Conclusions
In summary, two compartmental models of Phenylalanine (Phe) and Ty-
rosine (Tyr) metabolism in healthy subjects were developed, by using two
stable isotope tracer pulses administered intravenously. Kinetic analysis was
performed on the three tracer responses in plasma expressed by tracer-tracee
ratios and obtained by LC-MS/MS by isotope dilution. As far as the sim-
plest model (Model 1) is concerned, even though some of the variables of
the model are not a priori identifiable, it provides an important and physi-
ologically sound overview of Phe and Tyr metabolism (in terms of intervals
of validity) than the non-compartmental approaches presented in the past,
making the least number of possible structural assumptions. One of the
limit case scenarios (Model 1.a) described by this model shows results that
are compatible with those found using less structurally complex approaches.
Nevertheless, the other limit case scenario (Model 1.b) is likely to be better
representative of changes in protein synthesis and breakdown in tissues like
muscle, thanks to the development of a more complex and detailed com-
partmental model (Model 2). This last model provides accurate estimates
for all the unknown parameters, gathers innovative and detailed structural
informations for the metabolism of Phe-Tyr kinetics and was validated by
simulating a continuous infusion experiment previously done on pigs. The
models also allowed the identification of an issue related to the mixing prop-
erties of the accessible Tyr pool in the first minutes after the pulse injection,
not detectable by means of non-compartmental approaches.
The models presented in this thesis could serve not only as as a useful ref-
erence for a more complete and physiologically based overview of the Phe
and Tyr metabolic pathways but it could also guide future developments in
the modeling of amino acids characterized by resembling structural proper-
ties. By describing the postabsorptive whole body protein kinetics in healthy
humans, the models provide a direction to accurately and comprehensively
assess alterations in whole body protein synthesis and breakdown rates in
disease states.
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